BE2016C059I2 - - Google Patents

Download PDF

Info

Publication number
BE2016C059I2
BE2016C059I2 BE2016C059C BE2016C059C BE2016C059I2 BE 2016C059 I2 BE2016C059 I2 BE 2016C059I2 BE 2016C059 C BE2016C059 C BE 2016C059C BE 2016C059 C BE2016C059 C BE 2016C059C BE 2016C059 I2 BE2016C059 I2 BE 2016C059I2
Authority
BE
Belgium
Application number
BE2016C059C
Other languages
Dutch (nl)
Original Assignee
Novozymes Biopharma Dk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27394014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2016C059(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novozymes Biopharma Dk As filed Critical Novozymes Biopharma Dk As
Publication of BE2016C059I2 publication Critical patent/BE2016C059I2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A61P33/12—Schistosomicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
BE2016C059C 2000-04-12 2016-11-04 BE2016C059I2 (fa)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US22935800P 2000-04-12 2000-04-12
US19938400P 2000-04-25 2000-04-25
US25693100P 2000-12-21 2000-12-21
EP06076852A EP1832599A3 (en) 2000-04-12 2001-04-12 Albumin fusion proteins
EP01934875A EP1278767A4 (en) 2000-04-12 2001-04-12 ALBUMIN FUSED PROTEINS
EP08075909A EP2067488A1 (en) 2000-04-12 2001-04-12 Albumin fusion proteins

Publications (1)

Publication Number Publication Date
BE2016C059I2 true BE2016C059I2 (fa) 2020-08-20

Family

ID=27394014

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2016C059C BE2016C059I2 (fa) 2000-04-12 2016-11-04

Country Status (10)

Country Link
US (23) US20030171267A1 (fa)
EP (21) EP1803730A1 (fa)
JP (9) JP2003531590A (fa)
AU (7) AU2001264563A1 (fa)
BE (1) BE2016C059I2 (fa)
CA (8) CA2405563A1 (fa)
DK (2) DK2236152T3 (fa)
ES (2) ES2529300T3 (fa)
FR (1) FR16C0043I2 (fa)
WO (7) WO2001079444A2 (fa)

Families Citing this family (667)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
WO2002028877A1 (en) * 2000-09-29 2002-04-11 Human Genome Sciences, Inc. 24 human secreted proteins
WO2001032910A2 (en) * 1999-10-29 2001-05-10 Human Genome Sciences, Inc. 27 human secreted proteins
WO2001034627A1 (en) * 1999-11-12 2001-05-17 Human Genome Sciences, Inc. 28 human secreted proteins
US20020137890A1 (en) 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP0892047A3 (de) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Humanes und murines Semaphorin L
US20030166106A1 (en) * 1997-09-18 2003-09-04 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
JP4087563B2 (ja) * 1998-06-15 2008-05-21 ジーティーシー バイオセラピューティックス インコーポレイテッド エリスロポエチン類似体−ヒト血清アルブミン融合物
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20040199099A1 (en) * 1998-07-10 2004-10-07 Matson James R Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease
DE69926009D1 (de) 1998-10-13 2005-08-04 Univ Georgia Res Found Stabilisierte bioaktive peptide und methoden zu ihrer identifikation, synthese und verwendung
US20030190740A1 (en) 1998-10-13 2003-10-09 The University Of Georgia Research Foundation, Inc Stabilized bioactive peptides and methods of identification, synthesis, and use
EP1179059B1 (en) * 1999-05-05 2006-03-15 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US7592304B2 (en) 1999-10-01 2009-09-22 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
US7632803B2 (en) 1999-10-01 2009-12-15 Dmi Life Sciences, Inc. Metal-binding compounds and uses therefor
CA2389305A1 (en) * 1999-11-05 2001-05-17 Human Genome Sciences, Inc. 28 human secreted proteins
JP2003513663A (ja) * 1999-11-05 2003-04-15 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ２４個のヒト分泌タンパク質
EP3225632B1 (en) 1999-11-30 2020-05-06 Mayo Foundation for Medical Education and Research Antibodies binding to b7-h1, a novel immunoregulatory molecule
JP2003518075A (ja) 1999-12-24 2003-06-03 ジェネンテック・インコーポレーテッド 生理活性化合物の消失半減期延長のための方法及び組成物
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
US7291122B2 (en) * 2000-03-24 2007-11-06 Immunocept, L.L.C. Hemofiltration methods for treatment of diseases in a mammal
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7030219B2 (en) * 2000-04-28 2006-04-18 Johns Hopkins University B7-DC, Dendritic cell co-stimulatory molecules
EP1285066A1 (en) * 2000-05-12 2003-02-26 MERCK PATENT GmbH F-box containing protein
US6787040B2 (en) * 2000-05-16 2004-09-07 Immunocept, L.L.C. Method and system for colloid exchange therapy
WO2001090179A2 (en) * 2000-05-23 2001-11-29 Lexicon Genetics Incorporated Novel human thrombospondin-like proteins and polynucleotides encoding the same
EP1292619B1 (en) 2000-06-06 2008-02-06 Bristol-Myers Squibb Company B7-related nucleic acids and polypeptides and their uses for immunomodulation
US20030211513A1 (en) * 2000-06-08 2003-11-13 Henry Yue Intracellular signaling proteins
JP2004503220A (ja) * 2000-06-21 2004-02-05 アムジェン　インコーポレイテッド 分泌型結腸上皮間質性−１ポリペプチド、これをコードする核酸、およびその使用
EP1311669A4 (en) * 2000-08-18 2004-07-14 Human Genome Sciences Inc 11 HUMAN, ELIMINATED PROTEINS
AU2001229507A1 (en) * 2000-08-18 2002-03-04 Human Genome Sciences, Inc. 21 human secreted proteins
EP1317468A4 (en) * 2000-08-18 2004-07-07 Human Genome Sciences Inc 23 HUMAN SECRETED PROTEINS
CA2420902A1 (en) * 2000-08-28 2002-03-07 Craig A. Rosen 18 human secreted proteins
AU2001229563A1 (en) * 2000-09-20 2002-04-02 Human Genome Sciences, Inc. 21 human secreted proteins
AU2001296235A1 (en) * 2000-10-12 2002-04-22 Hyseq, Inc. Novel nucleic acids and polypeptides
US6531297B2 (en) * 2000-10-20 2003-03-11 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
US6949371B2 (en) 2000-10-20 2005-09-27 Applera Corporation Isolated human drug-metabolizing proteins, nucleic acid molecules encoding human drug-metabolizing proteins, and uses thereof
FR2815964A1 (fr) * 2000-10-30 2002-05-03 Inst Nat Sante Rech Med Proteine recepteur de la renine et/ou de la prorenine, acide nucleique codant pour ce recepteur et leur applications
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60128008T2 (de) 2000-12-05 2008-01-10 Wisconsin Alumni Research Foundation, Madison Rezeptor für ein toxin aus bacillus anthracis
MXPA03005036A (es) 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
US20030148920A1 (en) * 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
EP1354950A4 (en) * 2000-12-28 2005-01-12 Asahi Kasei Pharma Corp ACTIVATION GENE OF NF-KB
CA2433469A1 (en) * 2001-02-23 2002-09-06 Human Genome Sciences, Inc. 83 human secreted proteins
EP1365801A4 (en) * 2001-03-08 2004-10-13 Nuvelo Inc METHODS AND MATERIALS RELATING TO FIBULIN-RELATED POLYPEPTIDES AND POLYNUCLEOTIDES
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US7507413B2 (en) * 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20030125521A1 (en) 2001-06-20 2003-07-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
AU2002328853A1 (en) * 2001-07-06 2003-01-21 Geneprot, Inc. Carcinoma-related peptides
US7176278B2 (en) 2001-08-30 2007-02-13 Biorexis Technology, Inc. Modified transferrin fusion proteins
US8129504B2 (en) 2001-08-30 2012-03-06 Biorexis Technology, Inc. Oral delivery of modified transferrin fusion proteins
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
DE10251673A1 (de) 2001-11-09 2003-07-10 Hoffmann La Roche Alström-Syndrom-Gen, Genvarianten, codiertes Protein und Verfahren zur Diagnose des Alström-Syndroms
KR100406760B1 (ko) * 2001-11-16 2003-11-21 신코엠 주식회사 반도체 메모리 장치
WO2003051921A1 (en) 2001-12-17 2003-06-26 Applied Research Systems Ars Holding N.V. Chemokine mutants acting as chemokine antagonists
US20040082761A1 (en) * 2001-12-18 2004-04-29 Duggan Brendan M. Cell adhesion proteins
US20060253913A1 (en) * 2001-12-21 2006-11-09 Yue-Jin Huang Production of hSA-linked butyrylcholinesterases in transgenic mammals
US20080194481A1 (en) * 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
US7081446B2 (en) * 2002-01-31 2006-07-25 The Trustees Of Columbia University In The City Of New York Long-acting follicle stimulating hormone analogues and uses thereof
ZA200406124B (en) * 2002-02-07 2008-09-25 Delta Biotechnology Ltd Albumin-fused kunitz domain peptides
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US20050222023A1 (en) * 2002-02-07 2005-10-06 Hans-Peter Hauser Albumin-fused kunitz domain peptides
DE10205520A1 (de) * 2002-02-08 2003-08-14 Aventis Behring Gmbh Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease
JP4429728B2 (ja) * 2002-02-21 2010-03-10 ワイス エルエルシー フォリスタチン（ｆｏｌｌｉｓｔａｔｉｎ）ドメイン含有タンパク質
EP1483580A4 (en) * 2002-03-05 2006-10-11 Merck & Co Inc BIOMARKERS FOR THE EFFICACY OF APPETIZERS
US20030191056A1 (en) * 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
US20070015230A1 (en) * 2002-04-15 2007-01-18 Hammond David J Identification and characterization of analytes from whole blood
JP4585766B2 (ja) * 2002-04-15 2010-11-24 アメリカン ナショナル レッド クロス 混合物中のリガンドおよび標的を検出する方法
US7319138B2 (en) 2002-04-18 2008-01-15 The General Hospital Corporation Human DRG11-Responsive Axonal Guidance and Outgrowth of Neurite (DRAGON) proteins and variants thereof
US7141381B2 (en) 2002-04-25 2006-11-28 Bristol-Myers Squibb Company Human leucine-rich repeat-containing proteins specifically expressed in the nervous system
GB0210464D0 (en) 2002-05-08 2002-06-12 Svanborg Catharina Therapeutic treatment
AU2003243415A1 (en) * 2002-06-07 2003-12-22 Zymogenetics, Inc. Use of il-21 in cancer and other therapeutic applications
AU2003243394B2 (en) 2002-06-07 2008-06-12 Takeda Pharmaceutical Company Limited Prevention and reduction of blood loss
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
CN101172091B (zh) * 2007-09-25 2011-04-27 北京美福源生物医药科技有限公司 含人血清白蛋白与皮肤细胞生长因子的融合蛋白护肤产品制备工艺和用途
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
WO2004005520A1 (en) * 2002-07-03 2004-01-15 Nexgen Biotechnologies, Inc. Method for preparing fusion polypeptide comprising epidermal growth factor and human serum albumin in plants
EP1572130A4 (en) * 2002-07-08 2008-07-02 Genentech Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNEAL DISEASES
CA2493263A1 (en) * 2002-07-22 2004-01-29 Yamanouchi Pharmaceutical Co., Ltd. Novel gene associated with rheumatoid arthritis
GB0217033D0 (en) 2002-07-23 2002-08-28 Delta Biotechnology Ltd Gene and polypeptide sequences
CA2496002A1 (en) * 2002-08-07 2004-02-19 Delta Biotechnology Ltd. Albumin-fused ciliary neurotrophic factor
KR20050083627A (ko) * 2002-08-13 2005-08-26 아비오스 테크놀러지스 인코포레이티드 선택적 혈장 교환 치료
ES2709103T3 (es) 2002-08-28 2019-04-15 Dyax Corp Métodos para conservar órganos y tejidos
US9415102B2 (en) 2002-09-06 2016-08-16 Alexion Pharmaceuticals, Inc. High concentration formulations of anti-C5 antibodies
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
ES2614274T3 (es) * 2002-09-06 2017-05-30 Alexion Pharmaceuticals, Inc. Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5
US20060128615A1 (en) * 2002-09-18 2006-06-15 Pierrette Gaudreau Ghrh analogues
US7432351B1 (en) 2002-10-04 2008-10-07 Mayo Foundation For Medical Education And Research B7-H1 variants
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
AU2003292273A1 (en) * 2002-12-20 2004-07-14 Karolinska Institutet Innovations Ab Asthma susceptibility locus
CA2511522A1 (en) * 2002-12-26 2004-07-15 Takeda Pharmaceutical Company Limited Novel proteins and use thereof
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
EP2325302B1 (en) * 2003-02-11 2016-01-06 Shire Human Genetic Therapies, Inc. Cells that coexpress a sulfatase and a C-formylglycine generating enzyme and methods and uses thereof
EP1605961A4 (en) * 2003-03-12 2009-11-11 Vasgene Therapeutics Inc POLYPEPTIDE COMPOUNDS FOR INHIBITING ANGIOGENESIS AND TUMOR GROWTH
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US20070041987A1 (en) * 2003-03-19 2007-02-22 Daniel Carter Fragments or polymers of albumin with tunable vascular residence time for use in therapeutic delivery and vaccine development
BRPI0409554A (pt) * 2003-04-04 2006-04-25 Univ Lausanne peptacorpo de fusão isolado e recombinante, seqüência de dna, vetor, célula hospedeira, composição farmacêutica e seu uso, kits, método para a produção do peptacorpo de fusão e seqüência de intensificador
US7354584B2 (en) 2003-04-11 2008-04-08 Medimmune, Inc. Recombinant IL-9 antibodies
WO2004094589A2 (en) * 2003-04-18 2004-11-04 Incyte Corporation Secreted proteins
WO2004101620A2 (en) * 2003-05-01 2004-11-25 Compound Therapeutics, Inc. Serum albumin scaffold-based proteins and uses thereof
US6987270B2 (en) 2003-05-07 2006-01-17 General Electric Company Method to account for event losses due to positron range in positron emission tomography and assay of positron-emitting isotopes
WO2005001093A1 (ja) * 2003-06-30 2005-01-06 Nihon University 細胞外基質沈着タンパク質
WO2005010040A1 (en) 2003-07-15 2005-02-03 Barros Research Institute Eimeria tenella antigen for immunotherapy of coccidiosis
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
GB0320877D0 (en) * 2003-09-05 2003-10-08 Celltech R&D Ltd A protein involved in carcinoma
WO2005044306A2 (en) 2003-11-04 2005-05-19 Chiron Corporation Use of antagonist anti-cd40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
ATE539086T1 (de) * 2003-12-03 2012-01-15 Monika Kroez Interleukin-11-fusionsproteine
CN100379762C (zh) * 2003-12-08 2008-04-09 中国人民解放军军事医学科学院生物工程研究所 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US7371381B2 (en) 2003-12-12 2008-05-13 Amgen Inc. Anti-galanin antibodies and uses thereof
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
JPWO2005061704A1 (ja) * 2003-12-24 2007-07-12 武田薬品工業株式会社 癌の予防・治療剤
DK1729795T3 (en) * 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin fusion proteins
SE0400489D0 (sv) * 2004-02-27 2004-02-27 Biovitrum Ab Therapeutic proteins
WO2005085472A2 (en) * 2004-03-03 2005-09-15 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
CA2558439A1 (en) * 2004-03-11 2005-10-06 Kythera Biopharmaceuticals, Inc. Compositions and methods for preventing and treating skin and hair conditions
KR20120123619A (ko) 2004-03-12 2012-11-08 바스진 테라퓨틱스, 인크. 혈관형성 및 종양 성장을 억제하기 위한 폴리펩티드 화합물
US9592277B2 (en) * 2004-04-14 2017-03-14 Avirid, Inc. Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseases
MXPA06012260A (es) * 2004-04-23 2006-12-15 Conjuchem Biotechnologies Inc Metodo para la purificacion de conjugados de albumina.
KR100599454B1 (ko) * 2004-04-27 2006-07-12 재단법인서울대학교산학협력재단 종양 억제자로 작용하는 ａｉｍ3의 신규 용도
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
CA2568976A1 (en) * 2004-06-03 2005-12-22 Ciphergen Biosystems, Inc. Biomarkers for peripheral artery disease
US7906140B2 (en) * 2004-06-17 2011-03-15 Virun, Inc. Compositions for mucosal delivery of agents
US7456151B2 (en) 2004-07-14 2008-11-25 University Of Utah Research Foundation Promoting angiogenesis with netrin1 polypeptides
CN102680686A (zh) * 2004-08-13 2012-09-19 千年药品公司 用于鉴定、评估、预防和治疗前列腺癌的基因、组合物、试剂盒和方法
EP3073267A1 (en) 2004-09-21 2016-09-28 Medimmune, Inc. Antibodies against and methods for producing vaccines for respiratory syncytial virus
EP1799713B1 (en) * 2004-09-23 2014-11-05 VasGene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006039504A2 (en) * 2004-10-01 2006-04-13 Cell Ionix, Inc. Method and formulation for stem cells’ stimulation
SI3428191T1 (sl) 2004-10-06 2025-03-31 Mayo Foundation For Medical Education And Research B7-H1 in PD-1 v zdravljenju karcinoma ledvičnih celic
WO2006042197A2 (en) * 2004-10-11 2006-04-20 The Board Of Trustees Of The Leland Standford Junior University Use of del-1 in hair, bone and cartilage regeneration
US8071716B2 (en) * 2004-10-25 2011-12-06 Immune System Key Ltd. Thymus-specific protein
KR100583350B1 (ko) * 2004-11-03 2006-06-05 (주)넥스젠 Ｆａｓ-1 도메인을 함유하는 융합 단백질을 이용한상피세포재생인자의 생산 방법
EA011673B1 (ru) * 2004-11-09 2009-04-28 Арес Трейдинг С.А. Способ очистки fsh
EP2330200B1 (en) 2004-12-23 2017-04-05 Albumedix A/S Gene expression technique
JP5855326B2 (ja) 2005-01-06 2016-02-09 ノヴォ ノルディスク アー／エス 抗ｋｉｒ組み合わせ治療および方法
US20060178301A1 (en) * 2005-02-04 2006-08-10 Mathias Jurs Albumin-fused ciliary neurotrophic factor
CA2597924C (en) 2005-02-15 2018-10-02 Duke University Anti-cd19 antibodies and uses in oncology
US20110230407A1 (en) * 2005-03-14 2011-09-22 Alexander Yuzhakov Hepatocyte growth factor pathway activators in demyelinating diseases and central nervous system trauma
CN101137906A (zh) * 2005-03-23 2008-03-05 惠氏公司 对gdf-8调节剂的免疫应答的检测
US20060240487A1 (en) * 2005-03-23 2006-10-26 Nowak John A Detection of GDF-8 modulating agents
EP2360181B1 (en) 2005-04-18 2013-09-18 Novo Nordisk A/S IL-21 variants
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
DK1874821T3 (da) 2005-04-26 2013-07-08 Trion Pharma Gmbh Kombination af antistoffer med glykokortikoider til behandling af kræft
US9345745B2 (en) 2005-04-29 2016-05-24 Bo Wang Methods for treating inflammatory disorders and traumatic brain injury using stabilized non-hematopoietic EPO short peptides
US8653028B2 (en) 2005-04-29 2014-02-18 Rui Rong Yuan Erythropoietin-derived short peptide and its mimics as immuno/inflammatory modulators
US9585932B2 (en) 2005-04-29 2017-03-07 Peter C. Dowling Use of EPO-derived peptide fragments for the treatment of neurodegenerative disorders
EP2221316A1 (en) 2005-05-05 2010-08-25 Duke University Anti-CD19 antibody therapy for autoimmune disease
AU2006341530A1 (en) * 2005-05-12 2007-12-06 Zymogenetics, Inc. Methods of using PHHLA2 to co-stimulate T-cells
MX351401B (es) 2005-06-08 2017-10-13 Dana Farber Cancer Inst Inc Metodos y composiciones para el tratamiento de infecciones persistentes y cancer por inhibicion de la ruta de muerte celular programada (pd-1).
WO2007014167A2 (en) * 2005-07-22 2007-02-01 Five Prime Therapeutics, Inc. Compositions for and methods of treating epithelial diseases with growth factors
US8323666B2 (en) * 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
DK1919503T3 (en) 2005-08-10 2014-12-15 Macrogenics Inc Identification and preparation of antibodies with variant fc regions and methods of use thereof
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
RS57549B1 (sr) * 2005-08-26 2018-10-31 Ares Trading Sa Proces za pripremu glikoziliranog interferona beta
US7713715B2 (en) * 2005-09-06 2010-05-11 University Of Tennessee Research Foundation Method for diagnosing infections
US7855279B2 (en) * 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090099031A1 (en) * 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
WO2007038619A2 (en) * 2005-09-27 2007-04-05 Amunix, Inc. Proteinaceous pharmaceuticals and uses thereof
US7846445B2 (en) * 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
CN101321863A (zh) * 2005-10-03 2008-12-10 阿斯利康(瑞典)有限公司 具有受调控的血浆半衰期的融合蛋白
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
KR20080079301A (ko) * 2005-12-09 2008-08-29 시애틀 지네틱스, 인크. Ｃｄ４０ 결합제를 이용하는 방법
CA2625978A1 (en) * 2005-12-09 2007-06-14 Ares Trading S.A. Method for purifying fsh or a fsh mutant
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US8178495B2 (en) 2008-06-27 2012-05-15 Duke University Therapeutic agents comprising a GLP-1 receptor agonist and elastin-like peptide
JP2009520469A (ja) * 2005-12-22 2009-05-28 コンジュクヘム ビオテクフノロギエス インコーポレイテッド アルブミンと治療薬との前もって形成された抱合体の産生のための方法
US20100015642A1 (en) * 2006-01-05 2010-01-21 Kwon Eugene D B7-h1 and survivin in cancer
US20090215084A1 (en) * 2006-01-05 2009-08-27 Mayo Foundation For Medical Education And Research B7-h1 and b7-h4 in cancer
EP1989326A4 (en) 2006-01-17 2009-09-30 Health Research Inc BIO-HETERODUPLEX TRACKING TEST
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007097961A1 (en) * 2006-02-16 2007-08-30 Massachusetts Eye & Ear Infirmary Use of azurocidin inhibitors in prevention and treatment of ocular vascular leakage
US8389688B2 (en) 2006-03-06 2013-03-05 Aeres Biomedical, Ltd. Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
TW201333030A (zh) 2006-04-05 2013-08-16 Abbott Biotech Ltd 抗體之純化
DK2007885T3 (da) * 2006-04-11 2010-11-08 Csl Behring Gmbh Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
WO2007124361A2 (en) * 2006-04-20 2007-11-01 Mayo Foundation For Medical Education And Research Soluble b7-h1
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
AU2013202566C1 (en) * 2006-06-14 2018-07-12 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
EP1867660A1 (en) 2006-06-14 2007-12-19 CSL Behring GmbH Proteolytically cleavable fusion protein comprising a blood coagulation factor
WO2007144173A1 (en) * 2006-06-14 2007-12-21 Csl Behring Gmbh Proteolytically cleavable fusion protein comprising a blood coagulation factor
US7939632B2 (en) 2006-06-14 2011-05-10 Csl Behring Gmbh Proteolytically cleavable fusion proteins with high molar specific activity
CA2657277C (en) * 2006-07-13 2015-11-24 Upperton Limited Process for preparing particles of proteinaceous material
CN101511868B (zh) 2006-07-24 2013-03-06 比奥雷克西斯制药公司 毒蜥外泌肽融合蛋白
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
CN101578373A (zh) * 2006-09-06 2009-11-11 费斯生物制药公司 融合肽治疗组合物
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008088422A2 (en) * 2006-10-25 2008-07-24 Amgen Inc. Toxin peptide therapeutic agents
EP2091968A2 (en) 2006-10-26 2009-08-26 Novo Nordisk A/S Il-21 variants
CN101636179B (zh) 2006-11-07 2012-10-10 默沙东公司 Pcsk9拮抗剂
MX2009006398A (es) 2006-12-12 2009-06-23 Biorexis Pharmaceutical Corp Genotecas de proteinas de fusion de transferrina.
EP2557090A3 (en) 2006-12-19 2013-05-29 Ablynx N.V. Amino acid sequences directed against GPCRs and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
EP2102244A2 (en) 2006-12-19 2009-09-23 Ablynx N.V. Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
EP2097096B1 (en) * 2006-12-22 2017-05-31 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
EP1935430A1 (en) * 2006-12-22 2008-06-25 CSL Behring GmbH Modified coagulation factors with prolonged in vivo half-life
CA3161849A1 (en) 2007-01-30 2008-08-07 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
CA2678001C (en) * 2007-02-12 2017-07-11 Stefan Schulte Therapeutic application of kazal-type serine protease inhibitors
US8263353B2 (en) 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
HUE026728T2 (en) 2007-05-14 2016-06-28 Medimmune Llc A method for reducing eosinophil levels
JP5591691B2 (ja) * 2007-05-22 2014-09-17 アムジエン・インコーポレーテツド 生物活性を有する融合タンパク質を作製するための組成物及び方法
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2514762B1 (en) 2007-07-13 2015-04-08 The Johns Hopkins University B7-DC variants
AU2008275911A1 (en) * 2007-07-19 2009-01-22 Arizona Board of Regents, a body corporate acting for and on behalf of Arizona State University Self- anchoring MEMS intrafascicular neural electrode
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
HUE037489T2 (hu) 2007-08-29 2018-08-28 Sanofi Sa Humanizált anti-CXCR5 antitestek, azok származékai és alkalmazásuk
JP2009055838A (ja) * 2007-08-31 2009-03-19 Nipro Corp 融合タンパク質、該融合タンパク質に関連する遺伝子、ベクター、形質転換体及び抗炎症性医薬組成物
EP2853267B1 (en) * 2007-09-21 2016-12-07 The Regents of the University of California Targeted interferon demonstrates potent apoptotic and anti-tumor activities
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
WO2009053358A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying fc-fusion proteins
CA2701221A1 (en) * 2007-10-22 2009-04-30 Merck Serono S.A. Method for purifying an fc-containing protein
EP2225275A4 (en) 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
RU2490278C2 (ru) 2007-12-21 2013-08-20 Медиммун Лимитед ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
US20100311072A1 (en) * 2008-01-28 2010-12-09 Bristol-Myers Squibb Company Fluorescence polarization binding assay for characterizing glucokinase ligands
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
AR070315A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
US20110020325A1 (en) * 2008-02-29 2011-01-27 Kwon Eugene D Methods for reducing granulomatous inflammation
JP5020135B2 (ja) * 2008-03-19 2012-09-05 ソニーモバイルコミュニケーションズ， エービー 携帯端末装置およびコンピュータプログラム
US9242011B2 (en) 2008-04-01 2016-01-26 Novo Nordisk A/S Insulin albumin conjugates
CN102056945A (zh) 2008-04-07 2011-05-11 埃博灵克斯股份有限公司 针对Notch途径的单可变结构域
EP2439212B1 (en) 2008-05-02 2016-12-21 Novartis AG Improved fibronectin-based binding molecules and uses thereof
ES2531464T3 (es) * 2008-06-24 2015-03-16 Csl Behring Gmbh Factor VIII, factor de von Willebrand o sus complejos con semivida in vivo prolongada
AU2013202564B2 (en) * 2008-06-24 2015-09-17 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
CN102149379A (zh) 2008-07-10 2011-08-10 安吉翁生物医药有限公司 调节肝细胞生长因子(分散因子)活性的方法和肝细胞生长因子(分散因子)活性的小分子调节剂组合物
US9034325B2 (en) 2008-07-22 2015-05-19 Ablynx N.V. Amino acid sequences directed against multitarget scavenger receptors and polypeptides
CN102170906B (zh) 2008-08-05 2014-07-30 诺华股份有限公司 靶定补体蛋白c5的抗体的组合物和方法
WO2010027423A2 (en) 2008-08-25 2010-03-11 Amplimmune, Inc. Compositions of pd-1 antagonists and methods of use
EA201170375A1 (ru) * 2008-08-25 2012-03-30 Эмплиммьюн, Инк. Антагонисты pd-1 и способы их применения
EP2324060B1 (en) 2008-09-07 2015-07-22 Glyconex Inc. Anti-extended type i glycosphingolipid antibody, derivatives thereof and use
WO2010056804A1 (en) 2008-11-12 2010-05-20 Medimmune, Llc Antibody formulation
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
WO2010063011A2 (en) 2008-11-28 2010-06-03 Emory University Methods for the treatment of infections and tumors
FI4209510T3 (fi) 2008-12-09 2024-03-22 Hoffmann La Roche Anti-PD-L1-vasta-aineita ja niiden käyttö T-solutoiminnan tehostamiseksi
US8748115B2 (en) 2008-12-12 2014-06-10 Merck Sharp & Dohme Corp. PCSK9 immunoassay
WO2010080833A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
CN102378635A (zh) 2009-01-16 2012-03-14 特瓦制药工业有限公司 重组人白蛋白-人粒细胞集落刺激因子融合蛋白的新稳定制剂
WO2010087927A2 (en) 2009-02-02 2010-08-05 Medimmune, Llc Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
CN108530543B (zh) 2009-02-03 2023-06-23 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8680050B2 (en) * 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
ES2630253T3 (es) 2009-02-11 2017-08-18 Albumedix A/S Variantes de albúmina y conjugados
US8734796B2 (en) 2009-03-20 2014-05-27 Amgen Inc. Carrier immunoglobulins
WO2010128143A1 (en) 2009-05-07 2010-11-11 Novozymes Biopharma Dk A/S Method of controlling o-linked glycosylation of antibodies
WO2010138555A2 (en) * 2009-05-26 2010-12-02 University Of Florida Research Foundation, Inc. Small peptide expression system in mammalian cells
EP2258398A1 (en) * 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CA2769822C (en) 2009-08-13 2019-02-19 The Johns Hopkins University Methods of modulating immune function
US20120148557A1 (en) 2009-08-20 2012-06-14 Ulrich Kronthaler Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
AU2010290131C1 (en) * 2009-08-24 2015-12-03 Amunix Operating Inc. Coagulation factor VII compositions and methods of making and using same
US20110202016A1 (en) * 2009-08-24 2011-08-18 Arsenal Medical, Inc. Systems and methods relating to polymer foams
US10420862B2 (en) 2009-08-24 2019-09-24 Aresenal AAA, LLC. In-situ forming foams for treatment of aneurysms
US9173817B2 (en) 2009-08-24 2015-11-03 Arsenal Medical, Inc. In situ forming hemostatic foam implants
US9044580B2 (en) 2009-08-24 2015-06-02 Arsenal Medical, Inc. In-situ forming foams with outer layer
US8451450B2 (en) * 2009-09-14 2013-05-28 Bio-Rad Laboratories, Inc. Near real time optical phase conjugation
US20110172398A1 (en) 2009-10-02 2011-07-14 Boehringer Ingelheim International Gmbh Bispecific binding molecules for anti-angiogenesis therapy
UY32917A (es) 2009-10-02 2011-04-29 Boehringer Ingelheim Int Moléculas de unión a dll-4
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
WO2011051278A1 (en) * 2009-10-26 2011-05-05 Externautics S.P.A. Lung tumor markers and methods of use thereof
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
US8802827B2 (en) 2009-10-30 2014-08-12 Merck Sharp & Dohme Corp. AX1 PCSK9 antagonists
EP3421491A3 (en) 2009-10-30 2019-03-27 Albumedix Ltd Albumin variants
WO2011053783A2 (en) 2009-10-30 2011-05-05 Merck Sharp & Dohme Corp. Ax213 and ax132 pcsk9 antagonists and variants
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011060528A1 (en) * 2009-11-17 2011-05-26 Universite De Montreal Heteropeptides useful for reducing nonspecific adsorption
NZ703153A (en) * 2009-12-06 2015-02-27 Biogen Idec Hemophilia Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
NZ601034A (en) 2009-12-08 2013-07-26 Teva Pharma Bche albumin fusions for the treatment of cocaine abuse
EP3309176B1 (en) 2009-12-14 2025-10-01 Ablynx N.V. Immunoglobulin single variable domain antibodies against ox40l, constructs and their therapeutic use
EP2516664B1 (en) 2009-12-21 2015-07-22 Pharmathene Inc. Recombinant butyrylcholinesterases and truncates thereof
SI2521568T1 (sl) 2010-01-06 2019-01-31 Dyax Corp. Proteini, ki vežejo plazemski kalikrein
TWI513466B (zh) 2010-01-20 2015-12-21 Boehringer Ingelheim Int 抗凝血劑解毒劑
PL2525834T3 (pl) 2010-01-22 2020-10-19 Novo Nordisk Health Care Ag Hormony wzrostu o przedłużonej skuteczności in-vivo
RU2012134974A (ru) 2010-01-22 2014-02-27 Ново Нордиск Хелс Кеа Аг Стабилизированное соединение гормона роста
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
WO2011100460A2 (en) * 2010-02-11 2011-08-18 Ecole Polytechnique Federale De Lausanne Ccr7 ligand delivery and co-delivery in immunotherapy
JP5826194B2 (ja) 2010-03-03 2015-12-02 アブリンクス ナームローゼ フェンノートシャップ 二パラトープ性ａ−ベータ結合ポリペプチド
EP2371857A1 (en) 2010-04-01 2011-10-05 CSL Behring GmbH Factor XII inhibitors for treating interstitial lung disease
CN102939304B (zh) 2010-04-09 2017-04-19 阿尔布麦狄克斯公司 白蛋白衍生物和变体
SG185415A1 (en) 2010-05-06 2012-12-28 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
CA2798432A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein -related protein 6 (lrp6) antibodies
SG185354A1 (en) 2010-05-20 2012-12-28 Ablynx Nv Biological materials related to her3
UA126265C2 (uk) 2010-07-09 2022-09-14 Байовератів Терапьютікс Інк. Поліпептид фактора іх і спосіб його застосування
WO2012006623A1 (en) 2010-07-09 2012-01-12 Biogen Idec Hemophilia Inc. Systems for factor viii processing and methods thereof
WO2012019061A2 (en) 2010-08-05 2012-02-09 Stem Centrx, Inc. Novel effectors and methods of use
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (zh) 2010-08-10 2018-06-05 洛桑聚合联合学院 红细胞结合性治疗剂
ES2620255T3 (es) 2010-08-20 2017-06-28 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (HER3)
EP2608807A1 (en) 2010-08-27 2013-07-03 Stem Centrx, Inc. Notum protein modulators and methods of use
SG188328A1 (en) 2010-09-03 2013-04-30 Stem Centrx Inc Novel modulators and methods of use
US20120225081A1 (en) 2010-09-03 2012-09-06 Boehringer Ingelheim International Gmbh Vegf-binding molecules
US8993727B2 (en) 2010-09-22 2015-03-31 Amgen Inc. Carrier immunoglobulins and uses thereof
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
US8853490B2 (en) * 2010-10-26 2014-10-07 Pioneer Hi Bred International Inc Antifungal proteins and methods of use
CN103347893A (zh) 2010-11-01 2013-10-09 诺维信生物制药丹麦公司 白蛋白变体
PL2635607T3 (pl) 2010-11-05 2020-05-18 Zymeworks Inc. Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC
CU24111B1 (es) 2010-11-08 2015-08-27 Novartis Ag Polipéptidos que se enlazan a cxcr2
US9066974B1 (en) 2010-11-13 2015-06-30 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
US9095606B1 (en) 2010-11-13 2015-08-04 Sirbal Ltd. Molecular and herbal combinations for treating psoriasis
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
WO2012078813A2 (en) 2010-12-08 2012-06-14 Stem Centrx, Inc. Novel modulators and methods of use
ES2689753T3 (es) 2010-12-28 2018-11-15 Sumitomo Dainippon Pharma Co., Ltd Fármaco de diagnóstico y método de diagnóstico para la enfermedad de Alzheimer
US20120171195A1 (en) 2011-01-03 2012-07-05 Ravindranath Mepur H Anti-hla-e antibodies, therapeutic immunomodulatory antibodies to human hla-e heavy chain, useful as ivig mimetics and methods of their use
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
SA112330278B1 (ar) 2011-02-18 2015-10-09 ستيم سينتركس، انك. مواد ضابطة جديدة وطرق للاستخدام
US20140105898A1 (en) 2011-02-28 2014-04-17 Istituto Di Ricovero E Cura A Carattere Scientific Materno-Infantile Burlo Garo Apoptosis-inducing molecules and uses therefor
AU2012222833B2 (en) 2011-03-03 2017-03-16 Zymeworks Inc. Multivalent heteromultimer scaffold design and constructs
CA2829037C (en) 2011-03-09 2022-05-17 Csl Behring Gmbh Factor xii inhibitors for the administration with medical procedures comprising contact with artificial surfaces
EP2497489A1 (en) 2011-03-09 2012-09-12 CSL Behring GmbH Factor XII inhibitors for the treatment of silent brain ischemia and ischemia of other organs
JP2014509859A (ja) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
WO2012125775A1 (en) 2011-03-16 2012-09-20 Sanofi Uses of a dual v region antibody-like protein
US9340584B2 (en) 2011-03-29 2016-05-17 The General Hospital Corporation Engineered thioredoxin-like fold proteins
CA2827787A1 (en) 2011-03-30 2012-10-04 Boehringer Ingelheim International Gmbh Anticoagulant antidotes
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US20130078247A1 (en) 2011-04-01 2013-03-28 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to dii4 and ang2
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US9409987B2 (en) 2011-04-15 2016-08-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP2515112B1 (en) * 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
KR20140027307A (ko) 2011-05-05 2014-03-06 노보자임스 바이오파마 디케이 에이/에스 알부민 변이체
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
PT2717898T (pt) 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização
WO2012172495A1 (en) 2011-06-14 2012-12-20 Novartis Ag Compositions and methods for antibodies targeting tem8
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
ES2746052T3 (es) * 2011-06-28 2020-03-04 Inhibrx Lp Polipéptidos de fusión de serpina y métodos de uso de los mismos
CA2840552A1 (en) 2011-07-01 2013-01-10 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
CA2838964C (en) 2011-07-05 2021-07-13 Novozymes Biopharma Dk A/S Albumin formulation and use
CN103649116A (zh) 2011-07-08 2014-03-19 拜耳知识产权有限责任公司 释放松弛素的融合蛋白及其用途
PT2729160T (pt) 2011-07-08 2019-07-08 Aegerion Pharmaceuticals Inc Polipéptidos modificados com uma maior duração da ação e uma imunogenicidade reduzida
CN103930134B (zh) * 2011-07-18 2016-12-21 阿茨生物股份有限公司 长效促黄体激素(lh)化合物
RU2660370C2 (ru) 2011-07-22 2018-07-05 Цсл Беринг Гмбх Ингибирующие моноклональные антитела против фактора xii/xiia и их применения
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
CA2853951A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Antibodies and methods of treating cancer
US9221907B2 (en) 2011-11-01 2015-12-29 Bionomics Inc. Anti-GPR49 monoclonal antibodies
WO2013067057A1 (en) 2011-11-01 2013-05-10 Bionomics, Inc. Anti-gpr49 antibodies
US8993831B2 (en) * 2011-11-01 2015-03-31 Arsenal Medical, Inc. Foam and delivery system for treatment of postpartum hemorrhage
ES2697674T3 (es) 2011-11-01 2019-01-25 Bionomics Inc Procedimientos para bloquear el crecimiento de células madre cancerosas
HRP20211773T1 (hr) 2011-11-04 2022-03-04 Zymeworks Inc. Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
EP3252075A1 (en) 2011-11-04 2017-12-06 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
AU2012349735B2 (en) 2011-12-05 2016-05-19 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
TW201328707A (zh) 2011-12-05 2013-07-16 Novartis Ag 針對表皮生長因子受體３（ｈｅｒ３）之區域ｉｉ之ｈｅｒ３抗體
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
WO2013093762A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
AU2012318275B2 (en) 2011-12-22 2016-05-19 Csl Behring Gmbh Use of C1-inhibitor for the treatment of secondary edema of the central nervous system
US20130177574A1 (en) 2012-01-11 2013-07-11 Paul I. Terasaki Foundation Laboratory ANTI-HLA CLASS-Ib ANTIBODIES MIMIC IMMUNOREACTIVITY AND IMMUNOMODULATORY FUNCTIONS OF INTRAVENOUS IMMUNOGLOBULIN (IVIg) USEFUL AS THERAPEUTIC IVIg MIMETICS AND METHODS OF THEIR USE
US10800847B2 (en) 2012-01-11 2020-10-13 Dr. Mepur Ravindranath Anti-HLA class-IB antibodies mimic immunoreactivity and immunomodulatory functions of intravenous immunoglobulin (IVIG) useful as therapeutic IVIG mimetics and methods of their use
NZ626945A (en) 2012-01-12 2016-10-28 Biogen Ma Inc Chimeric factor viii polypeptides and uses thereof
EP2623110A1 (en) 2012-01-31 2013-08-07 CSL Behring GmbH Factor XII inhibitors for the treatment of neurological inflammatory disorders
CN104271148A (zh) 2012-02-15 2015-01-07 洛桑聚合联合学院 红细胞结合性治疗剂
DK3564260T5 (da) 2012-02-15 2024-09-02 Bioverativ Therapeutics Inc Faktor viii-sammensætninger og fremgangsmåder til fremstilling og anvendelse deraf
WO2013120939A1 (en) * 2012-02-15 2013-08-22 Csl Behring Gmbh Von willebrand factor variants having improved factor viii binding affinity
EP2822577B1 (en) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Recombinant factor viii proteins
SI2817338T1 (sl) 2012-02-24 2017-11-30 Abbvie Stemcentrx Llc Modulatorji DLL3 in postopki uporabe
AU2013226340B2 (en) 2012-02-27 2017-06-22 Ablynx N.V. CX3CR1-binding polypeptides
JP6441682B2 (ja) 2012-03-16 2018-12-19 アルブミディクス リミティド アルブミン変種
GB201204868D0 (en) * 2012-03-20 2012-05-02 San Raffaele Centro Fond Peptides
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス，インコーポレーテッド 代謝障害を治療するための組成物および方法
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
RU2713121C2 (ru) 2012-04-27 2020-02-03 Сайтомкс Терапьютикс, Инк. Активируемые антитела, которые связываются с рецептором эпидермального фактора роста, и способы их применения
WO2013166290A1 (en) 2012-05-04 2013-11-07 Abbvie Biotherapeutics Inc. P21 biomarker assay
US9328174B2 (en) 2012-05-09 2016-05-03 Novartis Ag Chemokine receptor binding polypeptides
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
US20130336973A1 (en) 2012-05-10 2013-12-19 Zymeworks Inc. Heteromultimer Constructs of Immunoglobulin Heavy Chains with Mutations in the Fc Domain
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
WO2013177386A1 (en) 2012-05-24 2013-11-28 Abbvie Biotherapeutics Inc. Biomarkers for predicting response to tweak receptor (tweakr) agonist therapy
US9398770B2 (en) 2012-05-30 2016-07-26 Bayer Cropscience Ag Compositions comprising a biological control agent and an insecticide
KR20150023478A (ko) 2012-05-30 2015-03-05 바이엘 크롭사이언스 아게 생물학적 방제제, 및 복합체 iii에서의 호흡 연쇄의 억제제로부터 선택된 살진균제를 포함하는 조성물
CN109169661B (zh) 2012-05-30 2021-09-21 拜耳作物科学股份公司 包括生物防治剂和杀昆虫剂的组合物
BR112014029221B1 (pt) 2012-05-30 2020-03-24 Bayer Cropscience Ag Composição que compreende um agente de controle biológico e um fungicida, seus usos, semente resistente a fitopatógeno, método para reduzir os danos totais em plantas e em partes de plantas, e kit de partes.
PL2854552T3 (pl) 2012-05-30 2019-11-29 Bayer Cropscience Ag Kompozycja zawierająca środek kontroli biologicznej i środek grzybobójczy wybrany spośród inhibitorów biosyntezy aminokwasów lub białek, inhibitorów wytwarzania ATP i inhibitorów syntezy ściany komórkowej
ES2689896T3 (es) 2012-05-30 2018-11-16 Bayer Cropscience Ag Composición que comprende un agente de control biológico y un fungicida
ES2689879T3 (es) 2012-05-30 2018-11-16 Bayer Cropscience Ag Composición que comprende un agente de control biológico y un fungicida seleccionado de inhibidores de la biosíntesis del ergosterol
EP3205210A1 (en) 2012-05-30 2017-08-16 Bayer CropScience Aktiengesellschaft Composition comprising a biological control agent and a fungicide selected from inhibitors of the succinate dehydrogenase
CN104470359B (zh) 2012-05-30 2017-05-24 拜尔农作物科学股份公司 包括一种生物防治剂和一种杀虫剂的组合物
EP3243387A3 (en) 2012-05-30 2017-12-13 Bayer CropScience Aktiengesellschaft Compositions comprising a biological control agent and an insecticide
AR091202A1 (es) 2012-05-30 2015-01-21 Bayer Cropscience Ag Composicion que comprende un agente de control biologico y un insecticida
PT2854549T (pt) 2012-05-30 2018-11-28 Bayer Cropscience Ag Composição que compreende um agente de controlo biológico e fluopicolida
EP2858659B1 (en) 2012-06-08 2019-12-25 Bioverativ Therapeutics Inc. Procoagulant compounds
JP2015525222A (ja) 2012-06-08 2015-09-03 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． キメラ性凝固因子
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US10656156B2 (en) 2012-07-05 2020-05-19 Mepur Ravindranath Diagnostic and therapeutic potential of HLA-E monospecific monoclonal IgG antibodies directed against tumor cell surface and soluble HLA-E
US10138291B2 (en) 2012-07-11 2018-11-27 Bioverativ Therapeutics Inc. Factor VIII complex with XTEN and von Willebrand Factor protein, and uses thereof
CN104768571B (zh) 2012-07-13 2018-11-09 酵活有限公司 多价异多聚体支架设计和构建体
US9345766B2 (en) 2012-08-30 2016-05-24 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-ERBB3 agents
CA2883272A1 (en) 2012-09-02 2014-03-06 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
CA2888806A1 (en) 2012-10-18 2014-04-24 Biogen Idec Ma Inc. Methods of using a fixed dose of a clotting factor
JP6487328B2 (ja) 2012-11-08 2019-03-20 アルブミディクス リミティド アルブミン変異体
CA2890438C (en) 2012-11-13 2022-10-18 Biontech Ag Agents for treatment of claudin expressing cancer diseases
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
WO2014084859A1 (en) 2012-11-30 2014-06-05 Novartis Ag Molecules and methods for modulating tmem16a activities
RS61648B1 (sr) 2012-12-05 2021-04-29 Novartis Ag Kompozicije i metode za antitela koja ciljaju epo
ES2875957T3 (es) 2012-12-20 2021-11-11 Amgen Inc Agonistas del receptor APJ y usos de los mismos
MX2015009141A (es) 2013-01-15 2016-03-16 Teva Pharma Formulaciones de albu-bche, preparacion y usos de las mismas.
KR101503907B1 (ko) * 2013-01-17 2015-03-20 서울대학교산학협력단 흉막폐렴균과 마이코플라즈마 하이오뉴모니아 감염 질환 예방을 위한 재조합 단백질 백신
KR101993714B1 (ko) 2013-01-30 2019-06-28 엔지엠 바이오파마슈티컬스, 아이엔씨. 대사 장애를 치료하는데 이용하기 위한 조성물과 방법
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
WO2014124361A1 (en) 2013-02-11 2014-08-14 Bayer Cropscience Lp Compositions comprising a streptomyces-based biological control agent and another biological control agent
LT2956477T (lt) 2013-02-15 2021-02-10 Bioverativ Therapeutics Inc. Optimizuotas faktoriaus viii genas
CN105007722A (zh) 2013-02-16 2015-10-28 诺维信生物制药丹麦公司 药代动力学动物模型
DK2961422T3 (en) 2013-02-28 2017-01-16 Csl Behring Gmbh Therapeutic agent for amniotic fluid embolism
US9255262B2 (en) * 2013-03-06 2016-02-09 Vision Global Holdings Ltd. Albumin-binding arginine deminase and the use thereof
USRE48805E1 (en) 2013-03-06 2021-11-02 Vision Global Holdings Ltd. Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein
ES2844189T3 (es) 2013-03-08 2021-07-21 Csl Behring Gmbh Tratamiento y prevención de lesiones remotas por isquemia-reperfusión
WO2014164703A1 (en) 2013-03-11 2014-10-09 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for occular inflammation
AU2013381687A1 (en) 2013-03-12 2015-09-24 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
WO2014165277A2 (en) 2013-03-12 2014-10-09 Amgen Inc. POTENT AND SELECTIVE INHIBITORS OF Nav1.7
EP2968391A1 (en) 2013-03-13 2016-01-20 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
US20160152686A1 (en) 2013-03-13 2016-06-02 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
US9302005B2 (en) 2013-03-14 2016-04-05 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
JP2016514130A (ja) 2013-03-14 2016-05-19 ノバルティス アーゲー Ｎｏｔｃｈ３に対する抗体
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
US9499614B2 (en) 2013-03-14 2016-11-22 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
CA2897334A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
US9562101B2 (en) 2013-06-21 2017-02-07 Novartis Ag Lectin-like oxidized LDL receptor 1 antibodies and methods of use
AR096601A1 (es) 2013-06-21 2016-01-20 Novartis Ag Anticuerpos del receptor 1 de ldl oxidado similar a lectina y métodos de uso
EA201592022A1 (ru) 2013-06-28 2016-05-31 Байоджен Ма Инк. Расщепляемый тромбином линкер, содержащий xten, и его применение
EP3013366B1 (en) 2013-06-28 2021-08-25 CSL Behring GmbH Combination therapy using a factor xii inhibitor and a c1-inhibitor
CN104342420B (zh) * 2013-07-30 2017-09-15 惠觅宙 一种重组长效人透明质酸酶、其编码基因、生产方法及应用
WO2015023894A1 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Recombinant factor viii proteins
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
US9387151B2 (en) 2013-08-20 2016-07-12 Anutra Medical, Inc. Syringe fill system and method
JP2016531915A (ja) 2013-08-28 2016-10-13 ステムセントリックス， インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
CA2922529A1 (en) 2013-08-28 2015-03-05 Stemcentrx, Inc. Novel sez6 modulators and methods of use
WO2015048330A2 (en) 2013-09-25 2015-04-02 Biogen Idec Ma Inc. On-column viral inactivation methods
CN103468662A (zh) * 2013-09-29 2013-12-25 惠觅宙 一种重组人透明质酸酶、其生产纯化方法、制剂及使用方法与应用
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
WO2015050663A1 (en) 2013-10-01 2015-04-09 Mayo Foundation For Medical Education And Research Methods for treating cancer in patients with elevated levels of bim
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
WO2015057403A2 (en) * 2013-10-17 2015-04-23 Tarix Pharmaceuticals Ltd. Compositions and methods for treatment of inflammatory bowel disease
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9540440B2 (en) 2013-10-30 2017-01-10 Cytomx Therapeutics, Inc. Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
DK3063275T3 (da) 2013-10-31 2019-11-25 Resolve Therapeutics Llc Terapeutiske nuklease-albumin-fusioner og fremgangsmåder
JP6306700B2 (ja) * 2013-11-01 2018-04-04 ユニバーシティ オブ オスロＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｏｓｌｏ アルブミン改変体及びその使用
US10584147B2 (en) 2013-11-08 2020-03-10 Biovertiv Therapeutics Inc. Procoagulant fusion compound
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US9737623B2 (en) 2013-12-11 2017-08-22 Cytomx Therapeutics, Inc. Antibodies that bind activatable antibodies and methods of use thereof
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
ES2902835T3 (es) 2014-01-09 2022-03-30 Hadasit Med Res Service Composiciones celulares mejoradas y métodos para la terapia contra el cáncer
SG10201913697UA (en) 2014-01-10 2020-03-30 Bioverativ Therapeutics Inc Factor viii chimeric proteins and uses thereof
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2015138628A1 (en) 2014-03-11 2015-09-17 University Of Florida Research Foundation, Inc. Use of aav-expressed m013 protein as an anti-inflammatory therapeutic
WO2015140591A1 (en) 2014-03-21 2015-09-24 Nordlandssykehuset Hf Anti-cd14 antibodies and uses thereof
WO2015160618A1 (en) 2014-04-16 2015-10-22 Bayer Cropscience Lp Compositions comprising ningnanmycin and a biological control agent
WO2015164615A1 (en) 2014-04-24 2015-10-29 University Of Oslo Anti-gluten antibodies and uses thereof
US20150316566A1 (en) 2014-05-02 2015-11-05 Cerenis Therapeutics Holding Sa Hdl therapy markers
US10302653B2 (en) 2014-05-22 2019-05-28 Mayo Foundation For Medical Education And Research Distinguishing antagonistic and agonistic anti B7-H1 antibodies
CN105198999A (zh) * 2014-05-27 2015-12-30 上海生物制品研究所有限责任公司 一种融合蛋白、其制备方法及其应用
USD774182S1 (en) 2014-06-06 2016-12-13 Anutra Medical, Inc. Anesthetic delivery device
USD763433S1 (en) 2014-06-06 2016-08-09 Anutra Medical, Inc. Delivery system cassette
USD750768S1 (en) 2014-06-06 2016-03-01 Anutra Medical, Inc. Fluid administration syringe
US10941182B2 (en) 2014-06-10 2021-03-09 Amgen Inc. Apelin polypeptides
PL3157548T3 (pl) 2014-06-18 2022-01-17 Csl Behring Gmbh Terapia z zastosowaniem inhibitora czynnika xii w zaburzeniu neurotraumatycznym
EP3157947A1 (en) 2014-06-23 2017-04-26 Novartis AG Hsa-gdf-15 fusion polypeptide and use thereof
CA2952293A1 (en) 2014-06-24 2015-12-30 Novo Nordisk A/S Mic-1 fusion proteins and uses thereof
WO2016004113A1 (en) 2014-06-30 2016-01-07 Biogen Ma Inc. Optimized factor ix gene
WO2016014148A1 (en) 2014-07-23 2016-01-28 Mayo Foundation For Medical Education And Research Targeting dna-pkcs and b7-h1 to treat cancer
CR20170027A (es) 2014-07-30 2017-05-09 Ngm Biopharmaceuticals Inc Composiciones y métodos de uso para tratar trastornos metabólicos
US9988443B2 (en) 2014-08-07 2018-06-05 Novartis Ag Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
US9771417B2 (en) 2014-08-07 2017-09-26 Novartis Ag Angiopoietin-like 4 antibodies and methods of use
KR102102789B1 (ko) 2014-08-22 2020-04-24 내셔널 청쿵 유니버시티 디스인테그린 변이체 및 이의 약학적 용도
EP3209130B1 (en) 2014-09-17 2023-03-01 BASF Corporation Compositions comprising recombinant bacillus cells and another biological control agent
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
AP2017009826A0 (en) 2014-09-26 2017-03-31 Bayer Pharma AG Stabilized adrenomedullin derivatives and use thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA3126536C (en) 2014-10-14 2023-07-25 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
MA40835A (fr) 2014-10-23 2017-08-29 Biogen Ma Inc Anticorps anti-gpiib/iiia et leurs utilisations
MA40861A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Anticorps anti-glycoprotéines iib/iiia
US20160130324A1 (en) * 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
PL3212226T3 (pl) 2014-10-31 2020-11-02 Ngm Biopharmaceuticals, Inc. Kompozycje i sposoby stosowania w leczeniu zaburzeń metabolicznych
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
UY36449A (es) 2014-12-19 2016-07-29 Novartis Ag Composiciones y métodos para anticuerpos dirigidos a bmp6
CA2971238C (en) 2014-12-23 2022-12-13 Merz Pharma Gmbh & Co. Kgaa Botulinum toxin prefilled container
EP3277725B1 (en) * 2015-03-30 2020-11-25 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
JP2016204292A (ja) * 2015-04-21 2016-12-08 国立大学法人 熊本大学 Ｂｍｐ７変異体とアルブミンとの融合体、及び該融合体を含む腎疾患治療剤
DK3288965T3 (da) * 2015-04-29 2019-09-23 Mediolanum Farm S P A Opløselig kimær interleukin-10 receptor og terapeutisk anvendelse deraf
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2016195723A1 (en) * 2015-06-03 2016-12-08 Beller Pharmaceuticals LLC Methods of treatment for conditions mediated by substance p
PE20180041A1 (es) 2015-06-05 2018-01-09 Novartis Ag Anticuerpos dirigidos a la proteina morfogenetica osea (bmp9) y metodos a partir de estos
WO2016201202A1 (en) * 2015-06-11 2016-12-15 Attwill Medical Solutions Inc. Medical devices, systems, and methods utilizing antithrombin-heparin compositions
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3328415B1 (en) * 2015-07-30 2020-11-25 Endor Technologies, S.L. Colony stimulating factor for use in pancreatic or colon cancer treatment
CA2994547A1 (en) 2015-08-03 2017-02-09 Bioverativ Therapeutics Inc. Factor ix fusion proteins and methods of making and using same
CN108350072B (zh) 2015-08-03 2022-05-24 诺华股份有限公司 治疗fgf21相关病症的方法
WO2017024198A1 (en) * 2015-08-06 2017-02-09 The Trustees Of The University Of Pennsylvania Glp-1 and use thereof in compositions for treating metabolic diseases
MX2018001825A (es) 2015-08-20 2018-05-07 Albumedix As Variantes y conjugados de albumina.
EP4374913A3 (en) 2015-09-08 2024-08-14 JCR Pharmaceuticals Co., Ltd. Novel human serum albumin mutant
WO2017042701A1 (en) 2015-09-09 2017-03-16 Novartis Ag Thymic stromal lymphopoietin (tslp)-binding antibodies and methods of using the antibodies
PL3347377T3 (pl) 2015-09-09 2021-07-19 Novartis Ag Przeciwciała wiążące limfopoetynę zrębu grasicy (tslp) i sposoby zastosowania tych przeciwciał
CN108430518A (zh) * 2015-09-11 2018-08-21 小利兰·斯坦福大学托管委员会 生物相关正交细胞因子/受体对
WO2017075045A2 (en) 2015-10-30 2017-05-04 Mayo Foundation For Medical Education And Research Antibodies to b7-h1
SI3383425T1 (sl) 2015-12-04 2020-11-30 Boehringer Ingelheim International Gmbh Biparatopični polipeptidi, ki antagonizirajo WNT-signaliziranje v tumorskih celicah
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
CA3008102A1 (en) 2015-12-18 2017-06-22 Novartis Ag Antibodies targeting cd32b and methods of use thereof
US20190000923A1 (en) 2015-12-22 2019-01-03 Novartis Ag Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
IL260218B2 (en) 2016-01-11 2023-04-01 Novartis Ag Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
EP3851457A1 (en) 2016-01-21 2021-07-21 Novartis AG Multispecific molecules targeting cll-1
IL320404A (en) 2016-02-01 2025-06-01 Bioverativ Therapeutics Inc Effective Factor VIII genes
EP3431508A4 (en) 2016-03-14 2019-08-14 JCR Pharmaceuticals Co., Ltd. SERUM ALBUMIN-20-K-GROWTH HORMONE FUSION PROTEIN
EP3432925A4 (en) 2016-03-22 2019-11-06 Bionomics Limited ADMINISTRATION OF A MONOCLONAL ANTI-LGR5 ANTIBODY
CA3016035A1 (en) 2016-03-31 2017-10-05 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
CN109071629A (zh) 2016-04-06 2018-12-21 杰特有限公司 治疗动脉粥样硬化的方法
JP7138567B2 (ja) 2016-04-27 2022-09-16 ノバルティス アーゲー 成長分化因子１５に対する抗体およびそれらの使用
PL3458478T3 (pl) 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Przeciwciała anty pd-1 i anty-lag3 do leczenia nowotworu
PE20190117A1 (es) 2016-05-24 2019-01-16 Novo Nordisk As Compuestos de mic-1 y usos de estos
AU2017283787B2 (en) 2016-06-15 2020-09-17 Novartis Ag Methods for treating disease using inhibitors of bone morphogenetic protein 6 (BMP6)
WO2018007601A1 (en) * 2016-07-08 2018-01-11 Csl Behring Recombinant Facility Ag Subcutaneous administration of long-acting factor ix in humans
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN109562149A (zh) 2016-08-05 2019-04-02 德国杰特贝林生物制品有限公司 C1酯酶抑制剂的药物制剂
EP3504648A1 (en) 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
US20210333279A1 (en) 2016-11-04 2021-10-28 Aarhus Universitet Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor
EP3541407A1 (en) * 2016-11-18 2019-09-25 Universitat de Barcelona Combined cd6 and imipenem therapy for treatment of infectious diseases and related inflammatory processes
WO2018096396A1 (en) 2016-11-22 2018-05-31 University Of Oslo Albumin variants and uses thereof
US12257288B2 (en) 2016-12-02 2025-03-25 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
EP3562840A1 (en) 2016-12-16 2019-11-06 Biogen MA Inc. Stabilized proteolytically activated growth differentiation factor 11
EP3360898A1 (en) 2017-02-14 2018-08-15 Boehringer Ingelheim International GmbH Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
EP3558370A2 (en) 2016-12-23 2019-10-30 Novartis AG Methods of treatment with anti-factor xi/xia antibodies
JP7456605B2 (ja) 2016-12-23 2024-03-27 プレジデント アンド フェローズ オブ ハーバード カレッジ Ｐｃｓｋ９の遺伝子編集
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
EA201991768A1 (ru) 2017-01-31 2020-01-22 Байоверетив Терапьютикс Инк. Слитые белки на основе фактора ix и способы их получения и пути применения
CA3052911A1 (en) 2017-02-08 2018-08-16 Novartis Ag Fgf21 mimetic antibodies and uses thereof
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
CN110770251A (zh) 2017-04-20 2020-02-07 诺和诺德股份有限公司 纯化白蛋白融合蛋白的方法
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
PE20200303A1 (es) 2017-05-24 2020-02-06 Novartis Ag Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer
AR111840A1 (es) 2017-05-31 2019-08-21 Boehringer Ingelheim Int Polipéptidos que antagonizan la señalización wnt en células tumorales
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
WO2018229715A1 (en) 2017-06-16 2018-12-20 Novartis Ag Compositions comprising anti-cd32b antibodies and methods of use thereof
PL3645034T3 (pl) 2017-06-29 2024-09-02 CSL Behring Lengnau AG 21-dniowy schemat dawkowania białek fuzyjnych zawierających czynnik ix i ludzką albuminę do profilaktycznego leczenia hemofilii i sposoby
CA3071852A1 (en) 2017-08-04 2019-02-07 Amgen Inc. Method of conjugation of cys-mabs
CN120905307A (zh) 2017-08-09 2025-11-07 比奥维拉迪维治疗股份有限公司 核酸分子及其用途
US11485781B2 (en) 2017-08-17 2022-11-01 Massachusetts Institute Of Technology Multiple specificity binders of CXC chemokines
JP7410019B2 (ja) 2017-09-15 2024-01-09 シーダーズ－サイナイ メディカル センター 臓器移植患者における臓器機能を改善するための方法
JP7793287B2 (ja) 2017-10-18 2026-01-05 シーエスエル リミティド ヒト血清アルブミン変異体およびその使用
EP3700933A1 (en) 2017-10-25 2020-09-02 Novartis AG Antibodies targeting cd32b and methods of use thereof
CN111479587B (zh) 2017-12-15 2024-01-09 杰特有限公司 FXIIa抑制剂在治疗肾纤维化和/或慢性肾脏疾病中的应用
WO2019129054A1 (zh) 2017-12-27 2019-07-04 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
JP7369127B2 (ja) 2017-12-28 2023-10-25 ナンジン レジェンド バイオテック カンパニー，リミテッド Ｔｉｇｉｔに対する単一ドメイン抗体及びその変異体
US11246908B2 (en) * 2018-01-10 2022-02-15 The Johns Hopkins University Compositions comprising albumin-FMS-like tyrosine kinase 3 ligand fusion proteins and uses thereof
TWI802633B (zh) 2018-01-15 2023-05-21 大陸商南京傳奇生物科技有限公司 針對pd-1之單域抗體及其變異體
US20210038744A1 (en) 2018-02-01 2021-02-11 Bioverativ Therapeutics Inc. Use of lentiviral vectors expressing factor viii
EP4253421A3 (en) 2018-03-13 2024-01-03 Zymeworks BC Inc. Anti-her2 biparatopic antibody-drug conjugates and methods of use
ES2953362T3 (es) * 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
BR112020018709A2 (pt) 2018-03-28 2021-01-05 Bristol-Myers Squibb Company Proteínas de fusão do receptor alfa de interleucina-2/interleucina-2 e métodos de uso
KR102876940B1 (ko) 2018-03-30 2025-10-24 난징 레전드 바이오테크 씨오., 엘티디. Lag-3에 대한 단일-도메인 항체 및 이의 용도
KR102119197B1 (ko) * 2018-04-23 2020-06-05 주식회사 엘베이스 세포에서의 자가포식작용 억제용 조성물, 및 이를 포함하는 종양성 질환의 예방 또는 치료용, 또는 항암제 내성 억제용 약학적 조성물
IL278538B2 (en) 2018-05-09 2024-01-01 Univ Chicago Compositions and methods concerning immune tolerance
MX2020012248A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de citocina activables y metodos de uso de los mismos.
CA3100007A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin-2 polypeptides and methods of use thereof
CN112512555A (zh) 2018-05-18 2021-03-16 比奥维拉迪维治疗股份有限公司 治疗血友病a的方法
EP3569618A1 (en) 2018-05-19 2019-11-20 Boehringer Ingelheim International GmbH Antagonizing cd73 antibody
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
PE20210320A1 (es) 2018-06-01 2021-02-16 Novartis Ag Moleculas de union contra bcma y usos de las mismas
WO2019246003A1 (en) 2018-06-18 2019-12-26 Anwita Biosciences, Inc. Anti-mesothelin constructs and uses thereof
PE20210632A1 (es) 2018-07-03 2021-03-23 Bristol Myers Squibb Co Formulaciones de fgf-21
WO2020033863A1 (en) 2018-08-09 2020-02-13 Bioverativ Therapeutics Inc. Nucleic acid molecules and uses thereof for non-viral gene therapy
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
MA53495A (fr) 2018-08-31 2021-12-08 Regeneron Pharma Stratégie de dosage permettant d'atténuer le syndrome de libération de cytokines pour des anticorps bispécifiques cd3/c20
EP3852874A1 (en) * 2018-09-17 2021-07-28 Kyoto University Administration of an anti-c5 agent for treatment of hepatic injury or failure
EP3856764A4 (en) 2018-09-27 2022-11-02 Xilio Development, Inc. MASKED CYTOKINE POLYPEPTIDES
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
AU2019369403B2 (en) 2018-10-29 2025-04-17 Spin Therapeutics, Llc Compositions and methods for alpha-1-antitrypsin disorders
EP3873500A4 (en) 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
GB201818477D0 (en) 2018-11-13 2018-12-26 Emstopa Ltd Tissue plasminogen activator antibodies and method of use thereof
EP3887393A1 (en) 2018-11-26 2021-10-06 Novartis AG Lpl-gpihbp1 fusion polypeptides
MX2021006648A (es) 2018-12-06 2021-07-07 Bioverativ Therapeutics Inc Uso de vectores lentivirales que expresan el factor ix.
CN114144433A (zh) 2019-03-22 2022-03-04 反射制药有限公司 用于目标蛋白的多价d-肽化合物
EP3941580A1 (en) 2019-03-22 2022-01-26 Reflexion Pharmaceuticals, Inc. D-peptidic compounds for vegf
EP3947442A2 (en) 2019-03-28 2022-02-09 Danisco US Inc. Engineered antibodies
SG11202110406SA (en) 2019-04-11 2021-10-28 Angion Biomedica Corp Solid forms of (e)-3-[2-(2-thienyl)vinyl]-1h-pyrazole
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
CN113891729A (zh) 2019-05-24 2022-01-04 赛诺菲 治疗系统性硬化症的方法
US20220387608A1 (en) 2019-06-18 2022-12-08 Bayer Aktiengesellschaft Adrenomedullin-analogues for long-term stabilization and their use
MX2022002637A (es) 2019-09-06 2022-03-25 Novartis Ag Proteinas de fusion terapeuticas.
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
JP2022549932A (ja) 2019-09-30 2022-11-29 バイオベラティブ セラピューティクス インコーポレイテッド レンチウイルスベクター製剤
CN114555646A (zh) 2019-10-17 2022-05-27 Jcr制药股份有限公司 血清白蛋白与生长激素的融合蛋白的制造方法
US20220378882A1 (en) 2019-10-30 2022-12-01 Jcr Pharmaceuticals Co., Ltd. Aqueous pharmaceutical composition containing fusion protein of serum albumin and growth hormone
EP4058471A1 (en) 2019-11-14 2022-09-21 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP4069200A1 (en) 2019-12-04 2022-10-12 Albumedix Ltd Methods and compositions produced thereby
IL293680B2 (en) 2019-12-13 2024-04-01 Synthekine Inc Il-2 orthologs and methods of use
US20210181200A1 (en) * 2019-12-17 2021-06-17 Women's College Hospital Ovarian cancer biomarker and methods of using same
US12358963B2 (en) 2019-12-24 2025-07-15 Juvena Therapeutics, Inc. Regenerative polypeptides and uses thereof
WO2021202473A2 (en) 2020-03-30 2021-10-07 Danisco Us Inc Engineered antibodies
BR112022020428A2 (pt) 2020-04-09 2023-03-07 Verve Therapeutics Inc Edição base do angptl3 e métodos de uso do mesmo para tratamento de doenças
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
US12116606B2 (en) 2020-06-14 2024-10-15 Vertex Pharmaceuticals Incorporated Complement factor I-related compositions and methods
TW202208619A (zh) 2020-06-24 2022-03-01 美商百歐維拉提夫治療公司 用於純化病毒載體之方法
TW202233668A (zh) 2020-10-21 2022-09-01 德商百靈佳殷格翰國際股份有限公司 用於治療眼部疾病之雙特異性抗-VEGF及抗-TrkB結合分子
KR20230088914A (ko) * 2020-10-30 2023-06-20 선전 프로트젠 엘티디. 질환 치료에서 인간 혈청 알부민의 응용
AU2021373366A1 (en) 2020-11-06 2023-06-01 Novartis Ag Cd19 binding molecules and uses thereof
CA3196844A1 (en) 2020-11-25 2022-06-02 Raphael Rozenfeld Tumor-specific cleavable linkers
CN114478800B (zh) * 2021-02-05 2022-10-11 华南理工大学 基于血清白蛋白的融合蛋白、纳米组装体及其制备方法和应用
AU2022224636A1 (en) 2021-02-19 2023-09-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that neutralize sars-cov-2
JP2024523033A (ja) 2021-06-17 2024-06-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規の三重特異的結合分子
KR20240029031A (ko) 2021-06-21 2024-03-05 쥬베나 테라퓨틱스, 인크. 재생 폴리펩티드 및 이의 용도
CN114133458B (zh) * 2021-12-08 2023-11-14 福州大学 一种在人血清白蛋白内部融合多肽的方法
IL316174A (en) 2022-04-26 2024-12-01 Novartis Ag Multiple specific antibodies targeting IL-13 and IL-18
WO2024013315A1 (en) 2022-07-15 2024-01-18 Boehringer Ingelheim International Gmbh Binding molecules for the treatment of cancer
WO2024015953A1 (en) 2022-07-15 2024-01-18 Danisco Us Inc. Methods for producing monoclonal antibodies
EP4605077A1 (en) 2022-10-18 2025-08-27 Confo Therapeutics N.V. Amino acid sequences directed against the melanocortin 4 receptor and polypeptides comprising the same for the treatment of mc4r-related diseases and disorders
WO2024130158A1 (en) 2022-12-16 2024-06-20 Modernatx, Inc. Lipid nanoparticles and polynucleotides encoding extended serum half-life interleukin-22 for the treatment of metabolic disease
TW202440624A (zh) * 2022-12-20 2024-10-16 澳大利亞商杰特創新股份有限公司 FcRn拮抗劑及其用途
EP4389762A1 (en) 2022-12-23 2024-06-26 Ospedale San Raffaele S.r.l. Inhibitors of dux4 activity and their use in therapy.
WO2024178305A1 (en) 2023-02-24 2024-08-29 Modernatx, Inc. Compositions of mrna-encoded il-15 fusion proteins and methods of use thereof for treating cancer
EP4442251A1 (en) 2023-04-05 2024-10-09 Albumedix Ltd Formulations and uses thereof
WO2025034806A1 (en) 2023-08-08 2025-02-13 Wisconsin Alumni Research Foundation Single-domain antibodies and variants thereof against fibroblast activation protein
WO2025072888A2 (en) 2023-09-28 2025-04-03 Novavax, Inc. Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Family Cites Families (702)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5625041A (en) * 1990-09-12 1997-04-29 Delta Biotechnology Limited Purification of proteins
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE2449885C3 (de) * 1974-10-21 1980-04-30 Biotest-Serum-Institut Gmbh, 6000 Frankfurt Verfahren zur Herstellung von chemisch modifizierten haltbaren Hämoglobinpräparaten sowie das nach diesem Verfahren hergestellte modifizierte Hämoglobinpräparat
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4363877B1 (en) 1977-09-23 1998-05-26 Univ California Recombinant dna transfer vectors
US4440859A (en) * 1977-05-27 1984-04-03 The Regents Of The University Of California Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms
US4264731A (en) * 1977-05-27 1981-04-28 The Regents Of The University Of California DNA Joining method
US4283489A (en) 1977-09-23 1981-08-11 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4407948A (en) 1977-09-23 1983-10-04 The Regents Of The University Of California Purification of nucleotide sequences suitable for expression in bacteria
US4366246A (en) 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4652525A (en) * 1978-04-19 1987-03-24 The Regents Of The University Of California Recombinant bacterial plasmids containing the coding sequences of insulin genes
US4447538A (en) * 1978-04-19 1984-05-08 Regents Of The University Of California Microorganism containing gene for human chorionic somatomammotropin
US5326859A (en) 1979-10-30 1994-07-05 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US5514567A (en) * 1979-01-30 1996-05-07 Juridical Foundation, Japanese Foundation For Cancer Research DNA and recombinant plasmid
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
AU538665B2 (en) 1979-10-30 1984-08-23 Juridical Foundation, Japanese Foundation For Cancer Research Human interferon dna
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
PH21848A (en) 1980-01-08 1988-03-17 Biogen Nv Dna sequences and recombinant dna molecules
GR74498B (fa) 1980-04-03 1984-06-28 Biogen Inc
DE3023787A1 (de) 1980-06-25 1982-01-21 Studiengesellschaft Kohle mbH, 4330 Mülheim Verfahren zur erhoehung der inkorporation und der expression von genetischem material in die kerne von intakten zellen mit hilfe von liposomen
US6610830B1 (en) 1980-07-01 2003-08-26 Hoffman-La Roche Inc. Microbial production of mature human leukocyte interferons
NZ198445A (en) 1980-09-25 1984-05-31 Genentech Inc Production of human fibroblast interferon by recombinant dna technology
ATE12348T1 (de) 1980-11-10 1985-04-15 Gersonde Klaus Prof Dr Verfahren zur herstellung von lipid-vesikeln durch ultraschallbehandlung, anwendung des verfahrens und vorrichtung zur durchfuehrung des verfahrens.
US4456748A (en) 1981-02-23 1984-06-26 Genentech, Inc. Hybrid human leukocyte interferons
EP0070906B1 (en) 1981-02-04 1986-10-15 Juridical Foundation Japanese Foundation For Cancer Research Human interferon-beta gene
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
NZ199722A (en) * 1981-02-25 1985-12-13 Genentech Inc Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain
JPS57149228A (en) 1981-03-11 1982-09-14 Ajinomoto Co Inc Novel erythropoietin and its preparation
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
CA1204682A (en) 1981-06-19 1986-05-20 Saran A. Narang Adaptors, and synthesis and cloning of proinsulin genes
US4792602A (en) 1981-06-19 1988-12-20 Cornell Research Foundation, Inc. Adaptors, and synthesis and cloning of proinsulin genes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
IL66614A (en) 1981-08-28 1985-09-29 Genentech Inc Method of constructing a dna sequence encoding a polypeptide,microbial production of human serum albumin,and pharmaceutical compositions comprising it
AU561343B2 (en) 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
EP0079739A3 (en) 1981-11-12 1984-08-08 The Upjohn Company Albumin-based nucleotides, their replication and use, and plasmids for use therein
EP0091527A3 (en) 1981-12-14 1984-07-25 The President And Fellows Of Harvard College Dna sequences, recombinant dna molecules and processes for producing human serum albumin-like polypeptides
JPS58107298A (ja) 1981-12-21 1983-06-25 Yoshitsuka Seiki:Kk 粉末成形プレスにおけるシエ−カ−カムの位相調整装置
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
IT1167610B (it) 1982-01-19 1987-05-13 Cetus Corp Interfreron ibrido multiclasse, composizione farmaceutica che lo contiene e procedimento di produzione
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
US4775622A (en) 1982-03-08 1988-10-04 Genentech, Inc. Expression, processing and secretion of heterologous protein by yeast
US4670393A (en) 1982-03-22 1987-06-02 Genentech, Inc. DNA vectors encoding a novel human growth hormone-variant protein
EP0091539B2 (en) 1982-03-31 1996-11-27 Ajinomoto Co., Inc. Gene coding for interleukin-2 polypeptide, recombinant DNA carrying said gene, cell lines possessing the recombinant DNA,and method for producing interleukin-2 using said cells
CA1341562C (en) 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US4778879A (en) 1982-04-20 1988-10-18 Sloan-Kettering Institute For Cancer Research Highly purified human interleukin 2 and method
US4925919A (en) * 1984-04-25 1990-05-15 Roland Mertelsmann Purified interleukin 2
US5824330A (en) 1982-04-20 1998-10-20 Sloan-Kettering Institute For Cancer Research Highly purified interleukin-2 and method
US4499188A (en) * 1982-05-05 1985-02-12 Cetus Corporation Bacterial production of heterologous polypeptides under the control of a repressible promoter-operator
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4490289A (en) 1982-09-16 1984-12-25 Hoffmann-La Roche Inc. Homogeneous human interleukin 2
JPS5945835U (ja) 1982-09-16 1984-03-27 株式会社東芝 回路しや断器の消弧装置
US4992271A (en) 1982-09-23 1991-02-12 Cetus Corporation Formulation for lipophilic IL-2 proteins
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
FI82266C (fi) 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
US4840934A (en) * 1983-01-25 1989-06-20 Eleanor Roosevelt Institute For Cancer Research, Inc. Therapeutic method using T cell growth factor
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4914026A (en) * 1983-04-07 1990-04-03 Chiron Corporation Alpha factor leader sequence directed secretion of insulin
DK172738B1 (da) 1983-04-07 1999-06-21 Chiron Corp Fremgangsmåde til at udtrykke modent insulin og DNA-struktur til anvendelse ved fremgangsmåden
US5015575A (en) * 1983-04-07 1991-05-14 Chiron Corporation Hybrid DNA synthesis of insulin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
WO1984004330A1 (en) 1983-04-22 1984-11-08 Amgen Secretion of exogenous polypeptides from yeast
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US5010003A (en) * 1983-04-25 1991-04-23 Genentech, Inc. Use of yeast homologous signals to secrete heterologous proteins
CA1196863A (en) * 1983-06-08 1985-11-19 Mattheus F.A. Goosen Slow release injectable insulin composition
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4576813A (en) 1983-07-05 1986-03-18 Monsanto Company Heat recovery from concentrated sulfuric acid
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6087792A (ja) 1983-09-23 1985-05-17 ジェネックス・コーポレイション 雑種制御領域
DE3483949D1 (de) 1983-09-26 1991-02-21 Udo Dr Med Ehrenfeld Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4518564A (en) * 1983-10-03 1985-05-21 Jeneric Industries, Inc. Gallium and silver free, palladium based dental alloys for porcelain-fused-to-metal restorations
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
JPS60115528A (ja) 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
GB8334102D0 (en) 1983-12-21 1984-02-01 Searle & Co Interferons with cysteine pattern
NZ210501A (en) * 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US4703008A (en) 1983-12-13 1987-10-27 Kiren-Amgen, Inc. DNA sequences encoding erythropoietin
US4855238A (en) 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
GB8334261D0 (en) 1983-12-22 1984-02-01 Bass Plc Fermentation processes
JPS60136596A (ja) 1983-12-26 1985-07-20 Suntory Ltd ペプチド及びこれを有効成分とする利尿剤
IT1185503B (it) 1984-01-11 1987-11-12 Univ New York Cloni di odna di eritropietina umana
US4908434A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Process for preparing purified interleukin-2
US4908433A (en) * 1984-04-25 1990-03-13 Sloan-Kettering Institute For Cancer Research Uses of interleukin-2
CA1213537A (en) 1984-05-01 1986-11-04 Canadian Patents And Development Limited - Societe Canadienne Des Brevets Et D'exploitation Limitee Polypeptide expression method
FR2564106B1 (fr) * 1984-05-09 1988-04-22 Transgene Sa Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
EP0172619A1 (en) 1984-06-20 1986-02-26 Takeda Chemical Industries, Ltd. Novel transformant and use thereof
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US5908763A (en) 1984-07-06 1999-06-01 Novartis Corporation DNA encoding GM-CSF and a method of producing GM-CSF protein
JPS61227526A (ja) 1984-07-25 1986-10-09 Chugai Pharmaceut Co Ltd 新規なコロニー刺激因子
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US4716217A (en) 1984-08-31 1987-12-29 University Patents, Inc. Hybrid lymphoblastoid-leukocyte human interferons
US4734491A (en) 1984-08-31 1988-03-29 University Patents, Inc. DNA sequences encoding hybrid lymphoblastoid-leukocyte human interferons
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
IL77081A (en) 1984-12-04 1999-10-28 Genetics Inst Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4677195A (en) 1985-01-11 1987-06-30 Genetics Institute, Inc. Method for the purification of erythropoietin and erythropoietin compositions
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
GB8504099D0 (en) * 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
DK129385A (da) 1985-03-22 1986-09-23 Novo Industri As Peptider og fremstilling deraf
FR2579224B1 (fr) * 1985-03-25 1987-05-22 Genetica Procede de preparation microbiologique de la serum-albumine humaine
US4751180A (en) * 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
CA1260858A (en) 1985-03-28 1989-09-26 Lawrence S. Cousens Expression using fused genes providing for protein product
DE3668186D1 (de) 1985-04-01 1990-02-15 Celltech Ltd Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert.
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8510219D0 (en) 1985-04-22 1985-05-30 Bass Plc Isolation of fermentation products
AU5890286A (en) 1985-06-17 1986-12-24 Genex Corp. Cloned human serum albumin gene
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
US5102872A (en) * 1985-09-20 1992-04-07 Cetus Corporation Controlled-release formulations of interleukin-2
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
JPH0618778B2 (ja) 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
JPS6296086A (ja) 1985-10-21 1987-05-02 Agency Of Ind Science & Technol 複合プラスミド
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
JPS63501765A (ja) 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
CA1295563C (en) 1985-11-01 1992-02-11 Robert T. Garvin Production of active proteins containing cystine residues
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
CA1295566C (en) 1987-07-21 1992-02-11 Robert T. Garvin Characterization and structure of genes for protease a and protease b from streptomyces griseus
US5641663A (en) * 1985-11-06 1997-06-24 Cangene Corporation Expression system for the secretion of bioactive human granulocyte macrophage colony stimulating factor (GM-CSF) and other heterologous proteins from steptomyces
JPH0780930B2 (ja) 1985-12-26 1995-08-30 三井石油化学工業株式会社 α−オレフインの重合方法
JPH0645551B2 (ja) 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
DE3771509D1 (de) 1986-01-22 1991-08-29 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die foerderung der wiederherstellung der haematopoietischen faehigkeit.
DE3777845D1 (de) 1986-01-22 1992-05-07 Chugai Pharmaceutical Co Ltd Pharmazeutischer stoff fuer die behandlung von myelogener leukaemie.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
FR2594846B1 (fr) 1986-02-21 1989-10-20 Genetica Procede de preparation de la serum albumine humaine mature
EP0237019A3 (en) 1986-03-14 1988-03-09 Toray Industries, Inc. Interferon conjugate and production thereof using recombinant gene
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IT1203758B (it) 1986-03-27 1989-02-23 Univ Roma Vettori di clonazione e di espressione di geni eterologhi in lieviti e lieviti trasformati con tali vettori
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
DK179286D0 (da) 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
US4765980A (en) * 1986-04-28 1988-08-23 International Minerals & Chemical Corp. Stabilized porcine growth hormone
US4859609A (en) 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US5028422A (en) * 1986-05-27 1991-07-02 Schering Corporation Treatment of basal cell carcinoma intralesionally with recombinant human alpha interferon
US5985599A (en) 1986-05-29 1999-11-16 The Austin Research Institute FC receptor for immunoglobulin
IT1204400B (it) * 1986-06-20 1989-03-01 Sclavo Spa Composizioni farmaceutiche contenente una calcitonina
GB8615701D0 (en) 1986-06-27 1986-08-06 Delta Biotechnology Ltd Stable gene integration vector
IT1196484B (it) 1986-07-11 1988-11-16 Sclavo Spa Vettore ad espressione e secrezione in lieviti,utile per la preparazione di proteine eterologhe
GR871067B (en) 1986-07-18 1987-11-19 Chugai Pharmaceutical Co Ltd Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
US4857467A (en) 1986-07-23 1989-08-15 Phillips Petroleum Company Carbon and energy source markers for transformation of strains of the genes Pichia
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US5002764A (en) * 1986-08-12 1991-03-26 Schering Corporation Treatment of actinic keratoses with alpha2 interferon
GB8620926D0 (en) * 1986-08-29 1986-10-08 Delta Biotechnology Ltd Yeast promoter
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4929442A (en) * 1986-09-26 1990-05-29 Exovir, Inc. Compositions suitable for human topical application including a growth factor and/or related materials
US5508031A (en) * 1986-11-21 1996-04-16 Cetus Oncology Corporation Method for treating biological damage using a free-radial scavenger and interleukin-2
WO1988007057A1 (en) 1987-03-13 1988-09-22 Amgen Inc. Purified platelet-derived growth factor and methods for purification thereof
US4835260A (en) * 1987-03-20 1989-05-30 Genetics Institute, Inc. Erythropoietin composition
WO1988008027A1 (en) * 1987-04-09 1988-10-20 Delta Biotechnology Limited Yeast vector
DE3855504T2 (de) 1987-04-22 1997-01-23 Chiron Corp Rekombinante Herstellung von A-Ketten-Polypeptiden von PDGF
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US4994560A (en) 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5489425A (en) 1987-06-24 1996-02-06 The Dow Chemical Company Functionalized polyamine chelants
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
NO302485B1 (no) 1987-07-28 1998-03-09 Gist Brocades Bv Fremgangsmåte for fremstilling av et polypeptid av interesse i en Klyveromyces vertscelle, transformert Klyveromyces vertscelle og anvendelse derav, plasmid og DNA konstruksjon
JPH0622784Y2 (ja) 1987-08-04 1994-06-15 東洋シヤッター株式会社 オ−バ−ドア用可動中柱の高さ調整装置
JP2627899B2 (ja) 1987-08-19 1997-07-09 株式会社 ビタミン研究所 遺伝子封入リポソームの製法
SE459586B (sv) 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
PT88641B (pt) 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
JPH0811074B2 (ja) 1987-10-30 1996-02-07 財団法人化学及血清療法研究所 プレアルブミンをコードする遺伝子を組込んだ組換えプラスミドおよびこれを用いたプレアルブミンの製法
GB8726953D0 (en) 1987-11-18 1987-12-23 Delta Biotechnology Ltd Yeast expression system
JP2791418B2 (ja) 1987-12-02 1998-08-27 株式会社ミドリ十字 異種蛋白質の製造方法、組換えｄｎａ、形質転換体
US5282856A (en) 1987-12-22 1994-02-01 Ledergerber Walter J Implantable prosthetic device
PT89484B (pt) 1988-01-22 1994-03-31 Gen Hospital Corp Genes clonados codificadores de proteinas de fusao ig-cd4 e sua utilizacao
JPH01240191A (ja) * 1988-02-16 1989-09-25 Green Cross Corp:The 酵母で機能する新規シグナルペプチドおよびこれを用いた異種蛋白質の分泌発現
JPH01215289A (ja) 1988-02-22 1989-08-29 Toa Nenryo Kogyo Kk 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法
US4999339A (en) * 1988-03-28 1991-03-12 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5066489A (en) 1988-03-28 1991-11-19 Cetus Corporation Combination therapy of IL-2 and DTIC for the treatment of melanoma
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5061488A (en) 1988-04-15 1991-10-29 The United States Of America As Represented Department Of Health & Human Services Flavone-8-acetic acid and interleukin-2 for cancer therapy
US5096707A (en) * 1988-04-15 1992-03-17 The United States Of America As Represented By The Department Of Health And Human Services Flavone-8-acetic acid and interleukin-2 in a method of treating certain cancers
US5096885A (en) * 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
IL89992A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human serum albumin in methylotrophic yeasts
IL89989A0 (en) 1988-04-25 1989-12-15 Phillips Petroleum Co Expression of human interleukin-2 in methylotrophic yeasts
US5126129A (en) * 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
ATE101620T1 (de) 1988-06-23 1994-03-15 Hoechst Ag Mini-proinsulin, seine herstellung und verwendung.
US5756065A (en) 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
PT90959B (pt) 1988-06-24 1995-05-04 Dow Chemical Co Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos
DE68921941T2 (de) 1988-06-24 1995-07-27 The Dow Chemical Co., Midland, Mich. Macrocyclische bifunktionelle Chelatbildner, Komplexe davon und ihre konjugierten Antikörper.
US5274119A (en) 1988-07-01 1993-12-28 The Dow Chemical Company Vicinal diols
DE68925893T2 (de) 1988-07-23 1996-08-08 Delta Biotechnology Ltd Sekretorische leader-sequenzen
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
FR2635115B1 (fr) 1988-08-05 1992-04-03 Rhone Poulenc Sante Procede de preparation de la serum albumine humaine a partir d'une levure
FR2649991B2 (fr) 1988-08-05 1994-03-04 Rhone Poulenc Sante Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces
EP0428615A4 (en) 1988-08-11 1991-11-13 California Biotechnology, Inc. Method for stabilizing heterologous protein expression and vectors for use therein
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP1026240A3 (en) 1988-09-02 2004-04-07 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5260202A (en) 1988-09-07 1993-11-09 Delta Biotechnology Limited Fermentation method
JPH02227079A (ja) 1988-10-06 1990-09-10 Tonen Corp ヒト血清アルブミン断片
US5349052A (en) 1988-10-20 1994-09-20 Royal Free Hospital School Of Medicine Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor
US5298243A (en) 1988-10-20 1994-03-29 Denki Kagaku Kogyo Kabushiki Kaisha Colony stimulating factor-gelatin conjugate
JPH02117384A (ja) 1988-10-26 1990-05-01 Tonen Corp 酵母宿主によるヒト血清アルブミンａの製造
US5759802A (en) 1988-10-26 1998-06-02 Tonen Corporation Production of human serum alubumin A
WO1990004788A1 (en) 1988-10-28 1990-05-03 Genentech, Inc. Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US5696239A (en) 1988-10-31 1997-12-09 The Dow Chemical Company Conjugates possessing ortho ligating functionality and complexes thereof
US5342604A (en) 1988-10-31 1994-08-30 The Dow Chemical Company Complexes possessing ortho ligating functionality
US5256410A (en) 1988-12-01 1993-10-26 Schering Corporation Treatment of squamous cell carcinoma intralesionally with recombinant human alpha interferon
US4975271A (en) 1988-12-19 1990-12-04 Vipont Pharmaceutical, Inc. Muscosal delivery systems for treatment of periodontal disease
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
DK105489D0 (da) * 1989-03-03 1989-03-03 Novo Nordisk As Polypeptid
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
WO1990011296A1 (en) 1989-03-20 1990-10-04 The General Hospital Corporation Insulinotropic hormone
US5693622A (en) 1989-03-21 1997-12-02 Vical Incorporated Expression of exogenous polynucleotide sequences cardiac muscle of a mammal
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE165516T1 (de) 1989-03-21 1998-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5231020A (en) 1989-03-30 1993-07-27 Dna Plant Technology Corporation Genetic engineering of novel plant phenotypes
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
ES2034790T3 (es) * 1989-04-11 1993-04-01 Boehringer Ingelheim International Gmbh Empleo de al menos una citroquina para la preparacion de un medicamento para el tratamiento sistematico de lesiones preneoplasticas.
FI901810A7 (fi) 1989-04-13 1990-10-14 Vascular Laboratory Inc Puhtaan pro-urokinaasin plasminogeeniaktivaattorikompleksi, joka on sidottu ihmisen seerumialbumiiniin disulfidisillan välityksellä
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
GB8909916D0 (en) * 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
ATE92107T1 (de) 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
US5766883A (en) * 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
US5332671A (en) 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
DK0474727T3 (da) 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
EP0399816B1 (en) 1989-05-24 1995-12-20 Merck & Co. Inc. Purification and characterization of a glioma-derived growth factor
US5808003A (en) 1989-05-26 1998-09-15 Perimmune Holdings, Inc. Polyaminocarboxylate chelators
DE69021335T2 (de) * 1989-06-09 1996-04-11 Gropep Pty. Ltd., Adelaide Wachstumshormonfusionsproteine.
JPH0327320A (ja) 1989-06-26 1991-02-05 Ajinomoto Co Inc ヒトｂ細胞分化因子医薬組成物
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE3924746A1 (de) * 1989-07-26 1991-01-31 Behringwerke Ag Erythropoietin (epo)-peptide und dagegen gerichtete antikoerper
CU22222A1 (es) 1989-08-03 1995-01-31 Cigb Procedimiento para la expresion de proteinas heterologicas producidas de forma fusionada en escherichia coli, su uso, vectores de expresion y cepas recombinantes
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
GB8927480D0 (en) 1989-12-05 1990-02-07 Delta Biotechnology Ltd Mutant fungal strain detection and new promoter
ATE103932T1 (de) 1989-08-22 1994-04-15 Immunex Corp Fusionsprotein bestehend aus gm-csf und il-3.
US5073627A (en) * 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
US6063373A (en) * 1989-09-19 2000-05-16 Maxim Pharmaceuticals, Inc. Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
CA1340994C (en) * 1989-09-21 2000-05-16 Rudolf Edgar Dr. Falk Treatment of conditions and disease
IE66494B1 (en) 1989-09-26 1996-01-10 Immunex Corp Granulocyte-colony stimulating factor receptors
WO1991005052A1 (fr) 1989-09-28 1991-04-18 Leningradsky Gosudarstvenny Universitet Procede d'obtention d'un polypeptide presentant une activite d'interleukine-2 humaine, secrete par des cellules de levure, saccharomyces cerevisiae
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
FR2653020B1 (fr) 1989-10-17 1993-03-26 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des leucemies.
US5667986A (en) 1989-10-18 1997-09-16 Delta Biotechnology Limited Yeast promoter for expressing heterologous polypeptides
GB8924021D0 (en) 1989-10-25 1989-12-13 Celltech Ltd Recombinant dna method and vectors for the use therein
CA2044593C (en) 1989-11-03 2004-04-20 Kenneth L. Brigham Method of in vivo delivery of functioning foreign genes
US5676954A (en) 1989-11-03 1997-10-14 Vanderbilt University Method of in vivo delivery of functioning foreign genes
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
US5173408A (en) 1989-11-13 1992-12-22 Lange Louis George Iii Mammalian pancreatic cholesterol esterase
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
JPH03201987A (ja) 1989-12-29 1991-09-03 Tonen Corp ヒト血清アルブミン断片
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
EP0439442B1 (en) * 1990-01-25 1996-03-06 Washington University Factor x-laci hybrid protein
JPH04211375A (ja) 1990-02-05 1992-08-03 Ajinomoto Co Inc 合成遺伝子及びそれを用いたヒト血清アルブミンの製造法
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
US5208018A (en) * 1990-03-19 1993-05-04 Brigham And Women's Hospital Treatment of cachexia with interleukin 2
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018088A1 (en) 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
GB9013017D0 (en) 1990-06-11 1990-08-01 Mars Uk Ltd Compounds
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
HUT65846A (en) 1990-07-10 1994-07-28 Boehringer Ingelheim Int Method for preparation of o-glycosylated alpha-interferons and medicinal drugs containing it
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5225341A (en) 1990-07-19 1993-07-06 The Regents Of The University Of California Biologically safe plant transformation system using a ds transposon
US5202239A (en) * 1990-08-07 1993-04-13 Scios Nova Inc. Expression of recombinant polypeptides with improved purification
US5071872A (en) 1990-08-14 1991-12-10 The Ohio State University Research Foundation Method for improving interleukin-2 activity using aci-reductone compounds
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0546073T3 (da) 1990-08-29 1998-02-02 Genpharm Int Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5391183A (en) * 1990-09-21 1995-02-21 Datascope Investment Corp Device and method sealing puncture wounds
IT1242149B (it) 1990-09-27 1994-02-16 Consiglio Nazionale Ricerche Sequenza di nucleotidi codificante per una proteina umana con proprieta' regolative dell'angiogenesi
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0553244B8 (en) 1990-10-05 2005-06-08 Celldex Therapeutics, Inc. Targeted immunostimulation with bispecific reagents
JPH07108232B2 (ja) 1990-10-09 1995-11-22 エム・ディ・リサーチ株式会社 ペプチド又は蛋白質の製造方法
JPH0638771Y2 (ja) 1990-10-26 1994-10-12 株式会社カンセイ エアバック制御装置
ATE160379T1 (de) 1990-10-29 1997-12-15 Chiron Corp Bispezifische antikörper, verfahren zu ihrer herstellung und deren verwendungen
FR2668368B1 (fr) 1990-10-30 1995-03-10 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
JPH0638771A (ja) 1990-10-31 1994-02-15 Tonen Corp ヒトプロテインジスルフィドイソメラーゼ遺伝子の発現方法および該遺伝子との共発現によるポリペプチドの製造方法
US5353535A (en) 1990-11-05 1994-10-11 Plumly George W Floor type advertising apparatus
US5830452A (en) 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JP3366947B2 (ja) 1990-11-29 2003-01-14 アンスティテュ ナシオナル ド ラ ルシェルシュ アグロノミクーイ．エン．エル．アー． タイプ１ インターフェロン由来の新規変異体、それらの製造方法及びそれらの適用
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5272080A (en) * 1991-02-19 1993-12-21 Pharmavene, Inc. Production of butyrylcholinesterase
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5272070A (en) * 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
CA2062659A1 (en) 1991-03-12 1992-09-13 Yasutaka Igari Composition for sustained-release of erythropoietin
US5811396A (en) 1991-03-14 1998-09-22 The United States Of America As Represented By The Department Of Health And Human Services TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor
EP0506477B1 (en) 1991-03-28 1999-06-23 Merck & Co. Inc. Vascular endothelial cell growth factor C subunit
US5374617A (en) 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
ATE269401T1 (de) 1991-04-10 2004-07-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
EP0509841A3 (en) 1991-04-18 1993-08-18 Tonen Corporation Co-expression system of protein disulfide isomerase gene and useful polypeptide gene and process for producing the polypeptide using its system
CA2058820C (en) 1991-04-25 2003-07-15 Kotikanyad Sreekrishna Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells
WO1992019973A1 (en) 1991-04-26 1992-11-12 Surface Active Limited Novel antibodies, and methods for their use
US5330901A (en) 1991-04-26 1994-07-19 Research Corporation Technologies, Inc. Expression of human serum albumin in Pichia pastoris
FR2676070B1 (fr) 1991-04-30 1994-09-30 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisation.
US5646012A (en) * 1991-04-30 1997-07-08 Rhone-Poulenc Rorer S.A. Yeast promoter and use thereof
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5304473A (en) * 1991-06-11 1994-04-19 Eli Lilly And Company A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production
JPH07503124A (ja) 1991-06-14 1995-04-06 ゾーマ・コーポレーション 微生物によって生産される抗体断片とそれらの複合体
FR2677996B1 (fr) 1991-06-21 1993-08-27 Rhone Poulenc Rorer Sa Vecteurs de clonage et/ou d'expression preparation et utilisation.
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
AU2147192A (en) 1991-06-28 1993-01-25 Genentech Inc. Method of stimulating immune response using growth hormone
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JPH05292972A (ja) 1991-07-29 1993-11-09 Tonen Corp 改良された酵母発現系
EP0597010A4 (en) 1991-07-31 1996-12-27 Rhone Poulenc Rorer Int Transgenic protein production.
US5723719A (en) 1991-08-08 1998-03-03 Health Research Inc. Transgenic mouse as model for diseases involving dopaminergic dysfunction
DE4126968A1 (de) 1991-08-14 1993-02-18 Detlev Prof Dr Med Ganten Transgene ratten, die in ihrem genom mindestens ein menschliches gen enthalten, das an der blutdruckregulation beteiligt ist
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US6270989B1 (en) 1991-11-05 2001-08-07 Transkaryotic Therapies, Inc. Protein production and delivery
EP0611306B1 (en) * 1991-11-08 1998-07-08 Somatogen, Inc. Hemoglobins as drug delivery agents
US5786883A (en) * 1991-11-12 1998-07-28 Pilkington Barnes Hind, Inc. Annular mask contact lenses
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
US6348327B1 (en) * 1991-12-06 2002-02-19 Genentech, Inc. Non-endocrine animal host cells capable of expressing variant proinsulin and processing the same to form active, mature insulin and methods of culturing such cells
US5540923A (en) * 1991-12-06 1996-07-30 Landsforeningen Til Kraeftens Bekaemplse Interferon proteins
US5428139A (en) 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
JPH07506720A (ja) 1992-01-07 1995-07-27 アテナ　ニューロサイエンシーズ，　インコーポレイテッド アルツハイマー病のトランスジェニック動物モデル
GB9200417D0 (en) 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy
FR2686620B1 (fr) * 1992-01-27 1995-06-23 Rhone Poulenc Rorer Sa Serum-albumine humaine, preparation et utilisation.
FR2686900B1 (fr) * 1992-01-31 1995-07-21 Rhone Poulenc Rorer Sa Nouveaux polypeptides ayant une activite de stimulation des colonies de granulocytes, leur preparation et compositions pharmaceutiques les contenant.
FR2686899B1 (fr) * 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
FR2686901A1 (fr) 1992-01-31 1993-08-06 Rhone Poulenc Rorer Sa Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant.
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
PT627940E (pt) 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
US5230886A (en) 1992-03-18 1993-07-27 Trustees Of Boston University Tumor cell suppression
USRE37302E1 (en) 1992-03-19 2001-07-31 Novo Nordisk A/S Peptide
DK36492D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5460954A (en) 1992-04-01 1995-10-24 Cheil Foods & Chemicals, Inc. Production of human proinsulin using a novel vector system
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
EP0969016A2 (en) 1992-06-15 2000-01-05 Scios Inc. Glucagon-like peptide and insulinotropin derivates
US5686268A (en) * 1992-06-19 1997-11-11 Pfizer Inc. Fused proteins
US5505931A (en) 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
JP3269504B2 (ja) 1992-07-08 2002-03-25 三菱ウェルファーマ株式会社 ヒト血清アルブミンの製造方法
FR2694294B1 (fr) * 1992-07-30 1994-09-09 Rhone Poulenc Rorer Sa Promoteur de levure et son utilisateur.
AU686567C (en) 1992-07-31 2002-08-08 Genentech Inc. Human growth hormone aqueous formulation
US5602307A (en) 1992-08-12 1997-02-11 Baylor College Of Medicine Non-human animal having predefined allele of a cellular adhesion gene
DE4226971C2 (de) * 1992-08-14 1997-01-16 Widmar Prof Dr Tanner Modifizierte Pilzzellen und Verfahren zur Herstellung rekombinanter Produkte
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5728553A (en) 1992-09-23 1998-03-17 Delta Biotechnology Limited High purity albumin and method of producing
US5731490A (en) 1992-09-29 1998-03-24 The Ontario Cancer Institute Mutant mouse lacking the expression of interferon regulatory factor 1 (IRF-1)
AU5171293A (en) * 1992-10-14 1994-05-09 Regents Of The University Of Colorado, The Ion-pairing of drugs for improved efficacy and delivery
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US6221958B1 (en) * 1993-01-06 2001-04-24 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5489743A (en) 1993-01-19 1996-02-06 Amgen Inc. Transgenic animal models for thrombocytopenia
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
FR2701953B1 (fr) 1993-02-22 1995-05-24 Centre Nat Rech Scient Protéine de fusion multi-VIP et procédé de préparation de VIP recombinant.
US5441734A (en) 1993-02-25 1995-08-15 Schering Corporation Metal-interferon-alpha crystals
US5780021A (en) 1993-03-05 1998-07-14 Georgetown University Method for treating type 1 diabetes using α-interferon and/or β-i
US5869445A (en) * 1993-03-17 1999-02-09 University Of Washington Methods for eliciting or enhancing reactivity to HER-2/neu protein
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
WO1994024160A2 (en) 1993-04-21 1994-10-27 Brigham And Women's Hospital Erythropoietin muteins with enhanced activity
GB9308581D0 (en) 1993-04-26 1993-06-09 Univ Manitoba A method for induction of antigen-specific suppression of immune-response
HU219682B (hu) * 1993-05-21 2001-06-28 Novo Nordisk A/S. Módosított VII faktor
CA2164088C (en) 1993-06-07 2005-06-14 Gary J. Nabel Plasmids suitable for gene therapy
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
DK82893D0 (da) * 1993-07-08 1993-07-08 Novo Nordisk As Peptid
US5512459A (en) 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
DE69429011T2 (de) 1993-08-09 2002-07-11 Edward Baral Ein verfahren zum sensibilisieren von krebszellen zur durch killer-zellen vermittelte lyse
CN1057534C (zh) 1993-08-17 2000-10-18 柯瑞英-艾格公司 促红细胞生成素类似物
GB9317618D0 (en) 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
US5521086A (en) * 1993-09-16 1996-05-28 Cephalon, Inc. Secretion sequence for the production of a heterologous protein in yeast
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5459031A (en) 1993-11-05 1995-10-17 Amgen Inc. Methods for controlling sialic acid derivatives in recombinant glycoproteins
JPH09506262A (ja) 1993-12-08 1997-06-24 ジェンザイム・コーポレイション 特異的抗体の製造方法
EP0658568A1 (en) 1993-12-09 1995-06-21 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
WO1995016708A1 (en) 1993-12-17 1995-06-22 Novo Nordisk A/S Proinsulin-like compounds
DK144093D0 (fa) 1993-12-23 1993-12-23 Novo Nordisk As
ATE300610T1 (de) 1994-01-31 2005-08-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US5550214A (en) 1994-02-10 1996-08-27 Brigham And Women's Hospital Isolated antigenic oncogene peptide fragments and uses
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5932780A (en) 1994-02-28 1999-08-03 Yissum Research Development Company Of Hebrew University Of Jerusalem Transgenic non-human animal assay system for anti-cholinesterase substances
GB9404270D0 (en) 1994-03-05 1994-04-20 Delta Biotechnology Ltd Yeast strains and modified albumins
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
US5629286A (en) * 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
US5652352A (en) 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene
US5646113A (en) 1994-04-07 1997-07-08 Genentech, Inc. Treatment of partial growth hormone insensitivity syndrome
FR2719593B1 (fr) 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9409496D0 (en) 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
GB9411356D0 (en) 1994-06-07 1994-07-27 Delta Biotechnology Ltd Yeast strains
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
US5639642A (en) * 1994-06-16 1997-06-17 Novo Nordisk A/S Synthetic leader peptide sequences
US5623054A (en) 1994-06-23 1997-04-22 The General Hospital Corporation Crucifer AFT proteins and uses thereof
NZ290089A (en) 1994-07-27 1999-05-28 Queensland Inst Med Res Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines
JPH0853500A (ja) 1994-08-11 1996-02-27 Asahi Glass Co Ltd 融合タンパク質および該タンパク質をコードする遺伝子
JPH0851982A (ja) 1994-08-11 1996-02-27 Asahi Glass Co Ltd ヒト血清アルブミンをコードする改変された遺伝子
JPH0859509A (ja) 1994-08-16 1996-03-05 Teijin Ltd サイトメガロウイルス抗原血症治療剤およびサイトメガロウイルス感染症治療剤
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US6071923A (en) * 1994-09-16 2000-06-06 Bar-Ilan University Retinoyloxy aryl-substituted alkylene butyrates useful for the treatment of cancer and other proliferative diseases
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
FR2726471B1 (fr) * 1994-11-07 1997-01-31 Pf Medicament Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins
WO1996014328A1 (en) 1994-11-07 1996-05-17 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
FR2726576B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
AT403167B (de) 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5695750A (en) 1994-11-25 1997-12-09 The United States Of America As Represented By The Secretary Of The Army Compositions for use to deactivate organophosphates
AU700605B2 (en) 1994-12-07 1999-01-07 Bionebraska, Inc. Production of peptides using recombinant fusion protein constructs
AU4415796A (en) 1994-12-07 1996-06-26 Bionebraska, Inc. Production of c-terminal amidated peptides from recombinant protein constructs
WO1996018412A1 (en) * 1994-12-12 1996-06-20 Beth Israel Hospital Association Chimeric cytokines and uses thereof
US20010006943A1 (en) 1994-12-23 2001-07-05 Ejvind Jensen Protracted GLP-1 compositions
ATE234625T1 (de) 1994-12-23 2003-04-15 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
US5583415A (en) 1994-12-27 1996-12-10 Motorola, Inc. Apparatus for simulating high battery temperature for rechargeble battery systems
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US5928939A (en) 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5837281A (en) * 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
DE69637481T2 (de) 1995-04-27 2009-04-09 Amgen Fremont Inc. Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8
WO1996034095A1 (en) 1995-04-27 1996-10-31 Human Genome Sciences, Inc. Human tumor necrosis factor receptors
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
AU5724996A (en) 1995-05-05 1996-11-21 Eli Lilly And Company Single chain insulin with high bioactivity
EP0871672A4 (en) 1995-05-05 1999-05-12 Human Genome Sciences Inc CHIMIOKINE BETA-8, CHIMIOKINE BETA-1 AND PROTEIN 4 INFLAMMATORY FROM HUMAN ORIGINAL MACROPHAGES
US5728915A (en) 1995-05-08 1998-03-17 Children's Hospital, Inc. Transgenic mice which express simian SV 40 T-antigen under control of the retinoblastoma gene promoter
US5705151A (en) 1995-05-18 1998-01-06 National Jewish Center For Immunology & Respiratory Medicine Gene therapy for T cell regulation
US6387365B1 (en) * 1995-05-19 2002-05-14 Schering Corporation Combination therapy for chronic hepatitis C infection
US6001625A (en) 1995-05-19 1999-12-14 The United States Of America As Represented By The Secretary Of The Army Site-directed mutagenesis of esterases
US5741815A (en) * 1995-06-02 1998-04-21 Lai; Ching-San Methods for in vivo reduction of nitric oxide levels and compositions useful therefor
US5804162A (en) 1995-06-07 1998-09-08 Alliance Pharmaceutical Corp. Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients
US5728707A (en) * 1995-07-21 1998-03-17 Constantia Gruppe Treatment and prevention of primary and metastatic neoplasms with salts of aminoimidazole carboxamide
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5840542A (en) 1995-07-28 1998-11-24 Mogam Biotechnology Research Institute Method for manufacture of proinsulin with high export yield
DE19530865A1 (de) 1995-08-22 1997-02-27 Michael Dr Med Nauck Wirkstoff sowie Mittel zur parenteralen Ernährung
JPH0995455A (ja) 1995-09-29 1997-04-08 Sumitomo Pharmaceut Co Ltd 腎機能改善剤
US5849322A (en) 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5702717A (en) 1995-10-25 1997-12-30 Macromed, Inc. Thermosensitive biodegradable polymers based on poly(ether-ester)block copolymers
PT858343E (pt) 1995-11-02 2004-07-30 Schering Corp Terapia por infusao continua de uma dose baixa de citoquina
US6048964A (en) * 1995-12-12 2000-04-11 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins and stimulatory factors
US6080409A (en) 1995-12-28 2000-06-27 Dendreon Corporation Immunostimulatory method
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6110707A (en) 1996-01-19 2000-08-29 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US6087129A (en) 1996-01-19 2000-07-11 Betagene, Inc. Recombinant expression of proteins from secretory cell lines
WO1997026321A2 (en) 1996-01-19 1997-07-24 Board Of Regents, The University Of Texas System Recombinant expression of proteins from secretory cell lines
US5767097A (en) * 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US6150337A (en) 1996-01-23 2000-11-21 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by Ribavirin in activated T-lymphocytes
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5616724A (en) 1996-02-21 1997-04-01 Cephalon, Inc. Fused pyrrolo[2,3-c]carbazole-6-ones
DE19639601A1 (de) 1996-02-28 1997-09-04 Bayer Ag Parapockenviren, die Fremd-DNA enthalten, ihre Herstellung und ihre Verwendung in Impfstoffen
US6045788A (en) * 1996-02-28 2000-04-04 Cornell Research Foundation, Inc. Method of stimulation of immune response with low doses of IL-2
US5912229A (en) * 1996-03-01 1999-06-15 Novo Nordisk Als Use of a pharmaceutical composition comprising an appetite-suppressing peptide
WO1997031943A1 (en) 1996-03-01 1997-09-04 Novo Nordisk A/S Use of a pharmaceutical composition comprising an appetite-suppressing peptide
JP3794748B2 (ja) * 1996-03-04 2006-07-12 第一アスビオファーマ株式会社 メタノール代謝系を有する微生物の培養法
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
PT889949E (pt) 1996-03-13 2003-10-31 Delta Biotechnology Ltd Controlo de fermentacao
CA2248538A1 (en) 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
CA2248136A1 (en) 1996-03-21 1997-09-25 Human Genome Sciences, Inc. Human endometrial specific steroid-binding factor i, ii and iii
WO1997034911A1 (en) 1996-03-22 1997-09-25 Human Genome Sciences, Inc. Apoptosis inducing molecule ii
US6204022B1 (en) * 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
WO1997039132A1 (en) 1996-04-16 1997-10-23 University Of Miami Stabilized preparations of human troponins and modifications thereof, diagnostic assay methods and assay kits
EP1854481B1 (en) * 1996-04-23 2014-07-16 Chugai Seiyaku Kabushiki Kaisha Cerebral stroke/cerebral edema preventive or remedy containing IL-8 binding inhibitor as active ingredient
ES2151277T3 (es) * 1996-05-22 2000-12-16 Protarga Inc Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
US5919815A (en) 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6300065B1 (en) 1996-05-31 2001-10-09 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
CA2257118C (en) * 1996-06-11 2002-12-10 Boehringer Mannheim Gmbh Recombinant blood-coagulation proteases
US6110891A (en) 1996-06-21 2000-08-29 Alizyme Therapeutics Ltd. Lectin compositions and uses thereof
GB2318352A (en) 1996-06-25 1998-04-22 Dejan Markovic Polypeptides mimicking the activity of human erythropoietin
GB9613858D0 (en) 1996-07-02 1996-09-04 Cortecs Ltd Hydrophobic preparations
US5932547A (en) 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
US6110703A (en) 1996-07-05 2000-08-29 Novo Nordisk A/S Method for the production of polypeptides
EP0935001B2 (en) 1996-07-15 2011-08-10 Chugai Seiyaku Kabushiki Kaisha Novel vegf-like factors
PE99498A1 (es) 1996-07-26 1999-01-21 Novartis Ag Polipeptidos de fusion
AU3972797A (en) 1996-08-02 1998-02-25 Zymogenetics Inc. Testis-specific insulin homolog polypeptides
US6190533B1 (en) 1996-08-15 2001-02-20 Exxon Chemical Patents Inc. Integrated hydrotreating steam cracking process for the production of olefins
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
ATE412740T1 (de) 1996-08-16 2008-11-15 Human Genome Sciences Inc Menschliches alpha-endokin
EP2107109B1 (en) 1996-08-23 2012-06-20 Vegenics Pty Ltd Recombinant vascular endothelial cell growth factor D (VEGF-D)
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US5922761A (en) 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
AU4199597A (en) 1996-09-09 1998-04-02 Novo Nordisk A/S A cdna and peptide with relation to cancer and weight loss
US20020052309A1 (en) 1996-09-11 2002-05-02 Athanasius A. Anagnostou Method of treating endothelial injury
EP0961832A4 (en) * 1996-09-18 2003-02-26 Human Genome Sciences Inc HUMAN TUMOR NECROSIS FACTOR-TYPE RECEPTOR GENES
US6225290B1 (en) 1996-09-19 2001-05-01 The Regents Of The University Of California Systemic gene therapy by intestinal cell transformation
US5994112A (en) 1996-10-09 1999-11-30 Incyte Pharmaceuticals, Inc. Human protein tyrosine kinase
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955508A (en) * 1996-10-15 1999-09-21 Loyola University Of Chicago Method for the enhancement of lymphocyte activity against opportunistic microbial pathogens
EP1695986B1 (en) 1996-10-18 2016-12-14 Genentech, Inc. Anti-erb B2 antibodies
AU4988697A (en) 1996-10-24 1998-05-15 Vion Pharmaceuticals, Inc. Monophosphate prodrugs of beta-l-fd4c and beta-l-fddc as potent antiviral agents
EP1577391A1 (en) 1996-10-25 2005-09-21 Human Genome Sciences, Inc. Neutrokine alpha
JPH10134761A (ja) 1996-10-30 1998-05-22 Ebara Corp イオン注入装置及びイオン注入方法
US5908830A (en) * 1996-10-31 1999-06-01 Merck & Co., Inc. Combination therapy for the treatment of diabetes and obesity
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP1306092A3 (en) 1996-11-05 2003-05-07 Eli Lilly & Company Use of GLP-1 and analogs administered peripherally, in regulation of obesity
GB9623205D0 (en) * 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
JP2001504105A (ja) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ―１ペプチドの利用
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6130248A (en) 1996-12-30 2000-10-10 Bar-Ilan University Tricarboxylic acid-containing oxyalkyl esters and uses thereof
US5833994A (en) 1997-01-08 1998-11-10 Paracelsian, Inc. Use of the AH receptor and AH receptor ligands to treat or prevent cytopathicity of viral infection
US6261801B1 (en) 1997-01-14 2001-07-17 Human Genome Sceineces, Inc. Nucleic acids encoding tumor necrosis factor receptor 5
AU5549998A (en) * 1997-01-24 1998-08-18 Novo Nordisk A/S Synthetic leader peptide sequences
EP1012274B2 (en) 1997-01-28 2011-06-15 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap0-2l)
DE69800640T2 (de) 1997-01-29 2001-07-05 Polymasc Pharmaceuticals Plc, London Pegylationsverfahren
EP0981635A1 (en) 1997-02-13 2000-03-01 Applied Phytologics, Inc. Production of mature proteins in plants
GB2324529A (en) 1997-02-21 1998-10-28 Merck & Co Inc A combinatorial library based on a tetrapeptide substituted with aminomethylcoumarin for characterizing proteases
WO2001012775A2 (en) 1999-08-17 2001-02-22 Human Genome Sciences, Inc 25 human secreted proteins
US7026447B2 (en) * 1997-10-09 2006-04-11 Human Genome Sciences, Inc. 53 human secreted proteins
US6030961A (en) * 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
US6124495A (en) 1997-03-11 2000-09-26 Beacon Laboratories, Inc. Unsaturated oxyalkylene esters and uses thereof
US6110970A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Nitrogen-containing oxyalkylene esters and uses thereof
US6110955A (en) 1997-03-11 2000-08-29 Beacon Laboratories, Inc. Metabolically stabilized oxyalkylene esters and uses thereof
US5939455A (en) 1997-03-11 1999-08-17 Beacon Laboratories, Inc. Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives
US5846774A (en) 1997-03-21 1998-12-08 Bionebraska, Inc. Chlorella virus promoters
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
ATE200679T1 (de) 1997-04-14 2001-05-15 Micromet Ag Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
MY118835A (en) * 1997-04-18 2005-01-31 Ipsen Pharma Biotech Sustained release compositions and the process for their preparation
US6140368A (en) 1997-05-05 2000-10-31 The Regents Of The University Of California Naphthols useful in antiviral methods
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
WO1998054202A1 (en) 1997-05-30 1998-12-03 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr10
US6071743A (en) 1997-06-02 2000-06-06 Subsidiary No. 3, Inc. Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
CA2295991A1 (en) 1997-06-11 1998-12-17 Human Genome Sciences, Inc. Human tumor necrosis factor receptor tr9
GB9713412D0 (en) 1997-06-26 1997-08-27 Delta Biotechnology Ltd Improved protein expression strains
US5858719A (en) 1997-07-17 1999-01-12 Incyte Pharmaceuticals, Inc. Polynucleotides encoding human ATP binding-cassette transport protein and methods of use
ATE255634T1 (de) 1997-09-01 2003-12-15 Aventis Pharma Gmbh Rekombinantes humanes erythropoietin mit vorteilhaftem glykosylierungsmuster
HUP9701554D0 (en) 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6472373B1 (en) 1997-09-21 2002-10-29 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection
ATE230999T1 (de) 1997-09-21 2003-02-15 Schering Corp Kombinationstherapie zur entfernung von nachweisbarer hcv-rns in patienten mit chronischer hepatitis c-infection
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
KR100826621B1 (ko) 1997-09-23 2008-05-02 렌트슐러 비오테히놀로기 게엠베하 액상 인터페론-베타 제제
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
JP2001519179A (ja) * 1997-10-09 2001-10-23 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ５３個のヒト分泌タンパク質
WO1999023105A1 (en) 1997-11-03 1999-05-14 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
CA2309810C (en) 1997-12-03 2014-07-08 Roche Diagnostics Gmbh Erythropoietin with high specific activity
CA2312190A1 (en) 1997-12-05 1999-06-17 Eli Lilly And Company Glp-1 formulations
ATE261935T1 (de) * 1997-12-08 2004-04-15 Bristol Myers Squibb Co Neue metformin salze und verfahren
CA2312188C (en) 1997-12-08 2010-06-29 Lexigen Pharmaceuticals Corp. Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
KR100253916B1 (ko) 1997-12-29 2000-05-01 김충환 사람 인슐린 전구체의 제조방법
US5951996A (en) 1998-02-04 1999-09-14 Czeizler Zaharia; Veronica L. Treatment of chronic diffuse GI bleeding with erythropoietin
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
US6221378B1 (en) * 1998-02-10 2001-04-24 Generex Pharmaceuticals Incorporated Mixed micellar delivery system and method of preparation
ES2291017T3 (es) 1998-02-13 2008-02-16 Amylin Pharmaceuticals, Inc. Efectos inotropicos y diureticos de la exendina y glp-1.
WO1999043706A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Derivatives of glp-1 analogs
JP4072319B2 (ja) 1998-03-13 2008-04-09 ノヴォ ノルディスク アクティーゼルスカブ 安定化水溶性ペプチド溶液
AU3087599A (en) 1998-03-19 1999-10-11 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
DE19813802A1 (de) 1998-03-27 1999-11-11 Retro Tech Gmbh Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
GB9806631D0 (en) 1998-03-28 1998-05-27 Safeglass Europ Limited Safetyglass
WO1999053064A2 (en) 1998-04-13 1999-10-21 Modex Therapeutiques, S.A. Methods of delivering glp-1
CA2270320A1 (en) 1998-04-28 1999-10-28 Patricia Lee Brubaker Novel microsphere composition
US6251868B1 (en) 1998-04-30 2001-06-26 Teijin Limited Method for treating a human immunodeficiency virus infection
CN1119352C (zh) 1998-05-15 2003-08-27 中国科学院上海生物化学研究所 人血清白蛋白在毕赤酵母中的表达与纯化
BR9910505A (pt) 1998-05-15 2001-01-02 Schering Corp Terapia de combinação compreendendo ribavirina e interferon alfa em pacientes cândidos de tratamento antiviral tendo infecção crÈnica por hepatite c
US5970300A (en) * 1998-06-01 1999-10-19 Xerox Corporation Apparatus for applying scents to paper in a printer/copier
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
DK1083924T3 (da) 1998-06-12 2004-11-22 Amylin Pharmaceuticals Inc Glucagon-lignende peptid-1 (GLP-1) forbedrer beta-cellereaktion på glucose i individer med forringet glucosetolerance
JP4087563B2 (ja) * 1998-06-15 2008-05-21 ジーティーシー バイオセラピューティックス インコーポレイテッド エリスロポエチン類似体−ヒト血清アルブミン融合物
CN1105727C (zh) 1998-06-17 2003-04-16 上海海济医药生物工程有限公司 重组人血清白蛋白的生产方法
WO1999066936A1 (en) 1998-06-24 1999-12-29 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
EP1091979B1 (en) 1998-06-30 2006-09-20 Novo Nordisk A/S Seeding crystals for the preparation of peptides or proteins
JP2003526321A (ja) 1998-07-15 2003-09-09 ウイスコンシン アラムナイ リサーチ フオンデーシヨン 合成ベータ細胞による糖尿病の治療
EP1100530B1 (en) 1998-07-31 2003-10-08 Novo Nordisk A/S In-vitro stimulation of beta cell proliferation
GB9817084D0 (en) 1998-08-06 1998-10-07 Wood Christopher B A method for promoting extra-heptic production of proteins for the correction of hypoalbuminaemia,anaemia,thrombocytopenia and/or coagulation disorders
US7056734B1 (en) 1998-08-10 2006-06-06 The United States Of America As Represented By The Department Of Health And Human Services, Nih Differentiation of non-insulin producing cells into insulin producing cells by GLP-1 or exendin-4 and uses thereof
US6346543B1 (en) * 1998-08-17 2002-02-12 Aventis Pharma S.A. Use of a taxoid to treat abnormal cell proliferation in the brain
PL346317A1 (en) 1998-08-28 2002-01-28 Lilly Co Eli Method for administering insulinotropic peptides
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
US6193997B1 (en) * 1998-09-27 2001-02-27 Generex Pharmaceuticals Inc. Proteinic drug delivery system using membrane mimetics
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
EP1123306A4 (en) 1998-10-16 2002-07-03 Immunex Corp INHIBITORS OF BLOOD PLATE ACTIVATION AND GENERATION
EP1123313B2 (en) 1998-10-23 2018-01-10 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
WO2000026354A1 (en) 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
JP2002531089A (ja) 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US6294153B1 (en) 1998-12-21 2001-09-25 Generex Pharmaceuticals, Inc. Aerosol pharmaceutical formulation for pulmonary and nasal delivery
US6312665B1 (en) 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
DE69928006T2 (de) 1998-12-22 2006-07-13 Eli Lilly And Co., Indianapolis Lagerstabile flüssige zusammensetzungen von glucagon-ähnlichem peptid-1
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
US7465785B2 (en) * 1999-03-08 2008-12-16 Genentech, Inc. Polypeptide encoded by a nucleic acid over-expressed in melanoma
CA2370189A1 (en) 1999-04-09 2000-10-19 Craig A. Rosen 48 human secreted proteins
AU3957400A (en) 1999-04-16 2000-11-02 Novo Nordisk A/S Dry, mouldable drug formulation
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
US6348192B1 (en) * 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
DE19921537A1 (de) 1999-05-11 2000-11-23 Dieter Hoersch Verfahren zur Induzierung von Zellwachstum durch Verwendung geeigneter Mittel
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
AU754770B2 (en) 1999-05-17 2002-11-21 Conjuchem Biotechnologies Inc. Long lasting insulinotropic peptides
CZ20014123A3 (cs) 1999-05-19 2002-06-12 Lexigen Pharmaceuticals Corp. Exprese a export interferonů-alfa jako Fc fúzních proteinů
US6344180B1 (en) 1999-06-15 2002-02-05 Bionebraska, Inc. GLP-1 as a diagnostic test to determine β-cell function and the presence of the condition of IGT and type II diabetes
AU5325200A (en) 1999-06-21 2001-01-09 Eli Lilly And Company Synergistic use of thiazolidinediones with glucagon-like peptide-1 and agonists thereof to treat metabolic instability associated with non-insulin dependent diabetes
PE20010288A1 (es) 1999-07-02 2001-03-07 Hoffmann La Roche Derivados de eritropoyetina
AU774555B2 (en) 1999-07-19 2004-07-01 Gpc Biotech Inc. Chimeric polypeptides of serum albumin and uses related thereto
US20020048571A1 (en) * 1999-07-19 2002-04-25 Jeno Gyuris Chimeric polypeptides of serum albumin and uses related thereto
US7144574B2 (en) * 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
TWI260321B (en) 1999-09-22 2006-08-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
BR0014945A (pt) 1999-10-21 2004-08-31 Monsanto Co Modificação pós-traducional de proteìnas recombinantes produzidas em plantas
WO2001030320A1 (en) 1999-10-22 2001-05-03 Amgen Inc. Biodegradable microparticles with novel erythropoietin stimulating protein
ATE381343T1 (de) 1999-11-03 2008-01-15 Novo Nordisk As Verwendung eines wachstumshormons oder eines wachstumshormon-sekretion fördernden mittels zur appetit-unterdrückung bzw. sättigungsinduktion
CA2324801A1 (en) 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
US6569832B1 (en) * 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
EP1228214A2 (en) 1999-11-12 2002-08-07 MERCK PATENT GmbH Erythropoietin forms with improved properties
IL149933A0 (en) 1999-12-06 2002-11-10 Gen Hospital Corp Pancreatic stem cells and their use in transplantation
US20020025306A1 (en) 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
EP1125579A3 (en) 2000-01-18 2003-01-02 Pfizer Products Inc. Uses of agrp-melanocortin receptor binding modulating compounds
US7598222B2 (en) 2000-01-27 2009-10-06 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 compounds
AU2001228327A1 (en) 2000-01-31 2001-08-14 Novo-Nordisk A/S Crystallisation of a glp-1 analogue
CN1487836A (zh) 2000-03-14 2004-04-07 埃米林药品公司 胰高糖素样肽1(7-36)对胃窦幽门十二指肠能动性的影响
AU2001264563A1 (en) 2000-04-12 2001-10-30 Human Genome Sciences, Inc. Albumin fusion proteins
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050100991A1 (en) 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
CA2406807C (en) 2000-04-21 2010-04-06 Amgen Inc. Methods and compositions for the prevention and treatment of anemia
IL142707A0 (en) 2000-04-27 2002-03-10 Pfizer Prod Inc Methods of treating obesity using a neurotensin receptor ligand
MXPA02011303A (es) * 2000-05-15 2003-04-25 Hoffmann La Roche Nueva composicion farmaceutica.
CA2380423A1 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
ATE346093T1 (de) 2000-06-16 2006-12-15 Lilly Co Eli Analoge des glucagon ähnlichen peptid-1
EP1326630B1 (en) 2000-09-18 2008-05-28 Sanos Bioscience A/S Use of glp-2 peptides
US7101561B2 (en) * 2000-12-01 2006-09-05 Innogenetics N.V. Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use
AU2002221222A1 (en) 2000-12-04 2002-06-18 Biovitrum Ab Novel method and use
MXPA03005036A (es) * 2000-12-07 2003-09-05 Lilly Co Eli Proteinas de fusion glp-1.
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
AU3938402A (en) 2000-12-13 2002-06-24 Lilly Co Eli Chronic treatment regimen using glucagon-like insulinotropic peptides
US7070973B2 (en) 2000-12-26 2006-07-04 Board Of Regents Of The University Of Nebraska Butyrylcholinesterase variants and methods of use
WO2002066062A2 (en) 2001-02-01 2002-08-29 Drucker Daniel J Enhancement of glp-2 activity
KR100399337B1 (ko) 2001-02-07 2003-09-26 드림바이오젠 주식회사 단백질의 무세포 번역후수식법
AU2002235731A1 (en) 2001-03-07 2002-09-19 Novo Nordisk A/S Combined use of derivatives of glp-1 analogs and ppar ligands
US20020169128A1 (en) 2001-04-09 2002-11-14 Geroge Sigounas Erythropoietin ameliorates chemotherapy-induced toxicity in vivo
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
WO2002085406A1 (en) 2001-04-24 2002-10-31 Restoragen, Inc. Methods and compositions for treating conditions associated with insulin resistance
WO2002097038A2 (en) 2001-05-25 2002-12-05 Human Genome Sciences, Inc. Chemokine beta-1 fusion proteins
EP1542712A2 (en) 2001-06-01 2005-06-22 Eli Lilly And Company Glp-1 formulations with protracted time action
DK1397124T3 (da) 2001-06-20 2007-04-02 Merck Sante Sas Anvendelse af diabetesmidler til fremstilling af et lægemiddel med helende virkning
EP1412384B1 (en) 2001-06-28 2007-12-26 Novo Nordisk A/S Stable formulation of modified glp-1
CA2455963C (en) 2001-07-31 2017-07-04 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Glp-1, exendin-4, peptide analogs and uses thereof
US20040002468A1 (en) 2001-08-08 2004-01-01 Genzyme Corporation Methods of treating diabetes and other blood sugar disorders
JP2004537580A (ja) 2001-08-10 2004-12-16 エピックス メディカル， インコーポレイテッド 延長された循環半減期を有するポリペプチド結合体
KR100593348B1 (ko) 2001-08-23 2006-06-26 일라이 릴리 앤드 캄파니 글루카곤-유사 펩티드-1 유사체
WO2003030821A2 (en) 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
DK2279755T3 (da) * 2001-10-10 2014-05-26 Ratiopharm Gmbh Remodellering og glycokonjugering af fibroblastvækstfaktor (FGF)
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
KR101271635B1 (ko) 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
ES2545090T3 (es) 2001-12-21 2015-09-08 Human Genome Sciences, Inc. Proteínas de fusión de albúmina y GCSF
EP1458860A2 (en) 2001-12-21 2004-09-22 Nexia Biotechnologies, Inc. Production of butyrylcholinesterases in transgenic mammals
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
US20080167238A1 (en) 2001-12-21 2008-07-10 Human Genome Sciences, Inc. Albumin Fusion Proteins
EP1572936A2 (en) 2002-03-05 2005-09-14 Eli Lilly And Company Heterologous g-csf fusion proteins
DE60336555D1 (de) * 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US6913890B2 (en) * 2002-12-18 2005-07-05 Palo Alto Research Center Incorporated Process for preparing albumin protein conjugated oligonucleotide probes
EP1594530A4 (en) 2003-01-22 2006-10-11 Human Genome Sciences Inc HYBRID PROTEINS OF ALBUMIN
AU2004216476B2 (en) * 2003-02-27 2009-01-08 Takeda Pharmaceutical Company Limited Method for the validatable inactivation of pathogens in a biological fluid by irradiation
JP4629047B2 (ja) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー Ｇｌｐ−１アナログ複合タンパク質
DK1729795T3 (en) 2004-02-09 2016-04-11 Human Genome Sciences Inc Albumin fusion proteins
US20060051859A1 (en) 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
US7436410B2 (en) * 2005-04-01 2008-10-14 Seiko Epson Corporation System and method for programming a controller
MX2008001865A (es) 2005-08-12 2008-04-15 Human Genome Sciences Inc Proteinas de fusion de albumina.
US7438904B1 (en) 2005-10-04 2008-10-21 University Of Kentucky Research Foundation High-activity mutants of butyrylcholinesterase for cocaine hydrolysis and method of generating the same
CA2562249A1 (en) 2005-10-20 2007-04-20 University Of Ottawa Heart Institute Anf analogue
EP1816201A1 (en) * 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
WO2007146038A2 (en) 2006-06-07 2007-12-21 Human Genome Sciences, Inc. Albumin fusion proteins
PT2717898T (pt) * 2011-06-10 2019-05-20 Bioverativ Therapeutics Inc Compostos pró-coagulantes e processos para a sua utilização

Also Published As

Publication number Publication date
WO2001079258A1 (en) 2001-10-25
US9849162B2 (en) 2017-12-26
EP1274720A1 (en) 2003-01-15
DK2236152T3 (da) 2014-07-07
US7785599B2 (en) 2010-08-31
EP1276856A1 (en) 2003-01-22
EP2236152B1 (en) 2014-06-04
US20080261877A1 (en) 2008-10-23
US6994857B2 (en) 2006-02-07
CA2747325A1 (en) 2001-10-25
US20040171123A1 (en) 2004-09-02
CA2405557A1 (en) 2001-10-25
EP2275557A1 (en) 2011-01-19
US7482013B2 (en) 2009-01-27
AU2001266557A1 (en) 2001-10-23
WO2001079271A1 (en) 2001-10-25
US20030171267A1 (en) 2003-09-11
EP1274720A4 (en) 2004-08-18
US20130266553A1 (en) 2013-10-10
EP2206720A1 (en) 2010-07-14
WO2001077137A1 (en) 2001-10-18
WO2001079442A2 (en) 2001-10-25
US20080269125A1 (en) 2008-10-30
JP2014057589A (ja) 2014-04-03
EP2213743A1 (en) 2010-08-04
CA2405709A1 (en) 2001-10-25
US20030199043A1 (en) 2003-10-23
US20140004095A1 (en) 2014-01-02
US6905688B2 (en) 2005-06-14
EP2216409B1 (en) 2014-12-03
JP2011217750A (ja) 2011-11-04
ES2529300T3 (es) 2015-02-18
US20140010798A1 (en) 2014-01-09
US20080269128A1 (en) 2008-10-30
WO2001079443A2 (en) 2001-10-25
EP1278544A2 (en) 2003-01-29
FR16C0043I2 (fr) 2020-04-10
EP2357008A1 (en) 2011-08-17
US20090285816A9 (en) 2009-11-19
EP2236152A1 (en) 2010-10-06
JP2003530839A (ja) 2003-10-21
WO2001079443A3 (en) 2002-02-21
US20110280830A9 (en) 2011-11-17
US20120252732A1 (en) 2012-10-04
WO2001079444A3 (en) 2002-05-23
US20050266532A1 (en) 2005-12-01
JP2003530852A (ja) 2003-10-21
JP2004506407A (ja) 2004-03-04
FR16C0043I1 (fa) 2016-12-09
EP1832599A3 (en) 2007-11-21
EP2298355A2 (en) 2011-03-23
US20030219875A1 (en) 2003-11-27
JP2003531590A (ja) 2003-10-28
WO2001079480A1 (en) 2001-10-25
DK2216409T3 (en) 2015-01-05
US9775888B2 (en) 2017-10-03
US20050266533A1 (en) 2005-12-01
AU2001262942A1 (en) 2001-10-30
US20030125247A1 (en) 2003-07-03
US9821039B2 (en) 2017-11-21
US20080269126A1 (en) 2008-10-30
EP2295456A1 (en) 2011-03-16
AU2001259066A1 (en) 2001-10-30
CA2405701A1 (en) 2001-10-25
EP1278767A4 (en) 2003-11-12
WO2001079442A3 (en) 2002-06-06
US10080785B2 (en) 2018-09-25
AU2001264563A1 (en) 2001-10-30
EP1274719A4 (en) 2004-05-19
EP2067488A1 (en) 2009-06-10
AU2001274809A1 (en) 2001-10-30
EP1983055A1 (en) 2008-10-22
US8946156B2 (en) 2015-02-03
JP2003530847A (ja) 2003-10-21
US20120141415A1 (en) 2012-06-07
EP2267026A1 (en) 2010-12-29
EP2311872A1 (en) 2011-04-20
EP1278767A1 (en) 2003-01-29
EP2298355A3 (en) 2011-06-29
US20070287173A9 (en) 2007-12-13
US20100189686A1 (en) 2010-07-29
ES2484966T3 (es) 2014-08-12
WO2001079480A9 (en) 2003-09-18
US20080269127A1 (en) 2008-10-30
AU2001261024A1 (en) 2001-10-30
US20080267962A1 (en) 2008-10-30
EP1803730A1 (en) 2007-07-04
US20080131399A1 (en) 2008-06-05
JP2003530846A (ja) 2003-10-21
US20040010134A1 (en) 2004-01-15
EP2216409A1 (en) 2010-08-11
EP1276849A2 (en) 2003-01-22
WO2001077137A9 (en) 2002-05-02
JP2003530838A (ja) 2003-10-21
CA2405525A1 (en) 2001-10-25
AU2001259063A1 (en) 2001-10-30
CA2405912A1 (en) 2001-10-18
EP1276849A4 (en) 2004-06-09
EP1276756A1 (en) 2003-01-22
US20120141449A1 (en) 2012-06-07
US6926898B2 (en) 2005-08-09
US20180200346A1 (en) 2018-07-19
CA2405563A1 (en) 2001-10-25
EP1276756A4 (en) 2004-06-09
EP1276856A4 (en) 2004-06-09
WO2001079271A9 (en) 2002-02-28
US7507414B2 (en) 2009-03-24
WO2001079444A2 (en) 2001-10-25
CA2405550A1 (en) 2001-10-25
CA2405557C (en) 2013-09-24
EP1274719A2 (en) 2003-01-15
EP1278544A4 (en) 2004-08-18
EP1832599A2 (en) 2007-09-12
WO2001079258A9 (en) 2002-02-28

Similar Documents

Publication Publication Date Title
BE2016C059I2 (fa)
BE2014C009I2 (fa)
BE2013C060I2 (fa)
BE2010C009I2 (fa)
BE2011C032I2 (fa)
BE2010C018I2 (fa)
BRPI0112928B8 (fa)
JP2000347946A5 (fa)
BRPI0110940B8 (fa)
JP2003519921A5 (fa)
JP2003514716A5 (fa)
JP2001084274A5 (fa)
JP2001324678A5 (fa)
BE2014C025I2 (fa)
JP2001308306A5 (fa)
JP2002052130A5 (fa)
BRPI0113372A8 (fa)
JP2002199236A5 (fa)
JP2003505773A5 (fa)
JP2002015878A5 (fa)
JP2002006528A5 (fa)
JP2002104386A5 (fa)
JP2001211812A5 (fa)
JP2001296412A5 (fa)
JP2002183336A5 (fa)